<html lang="en" class="pb-page js" data-request-id="9523b061f1b2f214-GRU"><head data-pb-dropzone="head"><style type="text/css" nonce="9523b061f1b2f214-GRU">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script nonce="9523b061f1b2f214-GRU">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.21599296089563347"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Rheumatology|Hematology/Oncology|Cardiology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Hematology/Oncology General|Rheumatoid Arthritis|Cardiology General"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2109927","title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","category":"Research","type":"Original Article","topics":"Hematology/Oncology General|Rheumatoid Arthritis|Cardiology General","specialties":"Rheumatology|Hematology/Oncology|Cardiology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-01-27T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Rheumatology|Hematology/Oncology|Cardiology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Hematology/Oncology General|Rheumatoid Arthritis|Cardiology General\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2109927","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","doi":"10.1056/NEJMdo006348","issueDate":"2022-01-27T00:00Z","age":"6Months-1990","isFree":"n","topics":"Hematology/Oncology General|Rheumatoid Arthritis|Cardiology General","viewType":"Full","specialties":"Rheumatology|Hematology/Oncology|Cardiology"},{"type":"Quick Take","title":"CV and Cancer Risk with Tofacitinib in RA","doi":"10.1056/NEJMdo006347","issueDate":"2022-01-27T00:00Z","age":"6Months-1990","isFree":"n","topics":"Hematology/Oncology General|Rheumatoid Arthritis|Cardiology General","viewType":"Full","specialties":"Rheumatology|Hematology/Oncology|Cardiology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="9523b061f1b2f214-GRU">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);


</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis"><meta name="dc.Creator" content="Steven R. Ytterberg"><meta name="dc.Creator" content="Deepak L. Bhatt"><meta name="dc.Creator" content="Ted R. Mikuls"><meta name="dc.Creator" content="Gary G. Koch"><meta name="dc.Creator" content="Roy Fleischmann"><meta name="dc.Creator" content="Jose L. Rivas"><meta name="dc.Creator" content="Rebecca Germino"><meta name="dc.Creator" content="Sujatha Menon"><meta name="dc.Creator" content="Yanhui Sun"><meta name="dc.Creator" content="Cunshan Wang"><meta name="dc.Creator" content="Andrea B. Shapiro"><meta name="dc.Creator" content="Keith S. Kanik"><meta name="dc.Creator" content="Carol A. Connell"><meta name="dc.Description" content="Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as comp..."><meta name="Description" content="Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as comp..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-01-27"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2109927"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202201273860406"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2117663"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2109927">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2109927">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2109927">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | NEJM">
        <meta property="og:title" content="Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2109927">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/95d72be3-9229-47bb-aef1-86930d215152/nejmoa2109927_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/95d72be3-9229-47bb-aef1-86930d215152/nejmoa2109927_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine"><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-402" async="async" crossorigin="" importance="high" nonce="9523b061f1b2f214-GRU"></script>


    
    
        
        <meta property="og:description" content="Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse
cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving
tofacitinib as comp...">
        <meta name="twitter:description" content="Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse
cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving
tofacitinib as comp...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1958">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2109927">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2109927">
    
    







<meta name="pbContext" content=";issue:issue:doi\:10.1056/nejm_2022.386.issue-4;requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2109927;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><style type="text/css" id="bc_async_1750343056672">div[id='bc_home_trend'] {opacity:0.0;filter:alpha(opacity=0);}
</style><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2109927" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2109927" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/research-summary" class="ng-simple-menu_list-link">Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2109927" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2109927" class="inputDoi"><input type="hidden" value="S.R. Ytterberg and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:316-326" class="inputCitation"><input type="hidden" value="01-26-2022" class="inputEPubDate"><input type="hidden" value="January 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="9523b061f1b2f214-GRU"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Steven R.</span> <span property="familyName">Ytterberg</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Deepak L.</span> <span property="familyName">Bhatt</span>, <span property="honorificSuffix">M.D., M.P.H.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1278-6245" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1278-6245</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ted R.</span> <span property="familyName">Mikuls</span>, <span property="honorificSuffix">M.D., M.S.P.H.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gary G.</span> <span property="familyName">Koch</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Roy</span> <span property="familyName">Fleischmann</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jose L.</span> <span property="familyName">Rivas</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rebecca</span> <span property="familyName">Germino</span>, <span property="honorificSuffix">Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+6</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sujatha</span> <span property="familyName">Menon</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yanhui</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Cunshan</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrea B.</span> <span property="familyName">Shapiro</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Keith S.</span> <span property="familyName">Kanik</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Carol A.</span> <span property="familyName">Connell</span>, <span property="honorificSuffix">R.N., Ph.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the ORAL Surveillance Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-6</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">January 26, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">316</span>-<span property="pageEnd">326</span></div><div class="doi">DOI: 10.1056/NEJMoa2109927</div><div class="core-enumeration"><a href="/toc/nejm/386/4"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">4</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DSteven%2BR.%2BYtterberg%252C%2BDeepak%2BL.%2BBhatt%252C%2BTed%2BR.%2BMikuls%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D4%26contentID%3D10.1056%252FNEJMoa2109927%26title%3DCardiovascular%2Band%2BCancer%2BRisk%2Bwith%2BTofacitinib%2Bin%2BRheumatoid%2BArthritis%26publicationDate%3D01%252F27%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2109927" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DSteven%2BR.%2BYtterberg%252C%2BDeepak%2BL.%2BBhatt%252C%2BTed%2BR.%2BMikuls%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D4%26contentID%3D10.1056%252FNEJMoa2109927%26title%3DCardiovascular%2Band%2BCancer%2BRisk%2Bwith%2BTofacitinib%2Bin%2BRheumatoid%2BArthritis%26publicationDate%3D01%252F27%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/372c0c6f-d231-428e-aae0-2f2bf2af718e/nejmoa2109927.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2109927.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2109927" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2109927" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2109927.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor. Patients were randomly assigned in a 1:1:1 ratio to receive tofacitinib at a dose of 5 mg or 10 mg twice daily or a TNF inhibitor. The coprimary end points were adjudicated MACE and cancers, excluding nonmelanoma skin cancer. The noninferiority of tofacitinib would be shown if the upper boundary of the two-sided 95% confidence interval for the hazard ratio was less than 1.8 for the combined tofacitinib doses as compared with a TNF inhibitor.<div data-style-type="float-right"><div class="core-digital-object nejm-research-summary">
    <div class="ng-do-media" data-location="inlineArticlePreview">
        <div class="ng-do-media_item">
            <div class="ng-do-media_item-left">
                <a href="/do/10.1056/NEJMdo006348/full/" class="ng-do-media_item-img-link">
                    <img src="/cms/asset/6f37edf7-2dd9-44cd-a511-a6e754466de6/nejmdo006348_thumb.jpg" class="ng-do-media_item-img">
                </a>
            </div>
            <div class="ng-do-media_item-right">
                <div class="ng-do-media_item-type">
                    <a href="/browse/nejm-media-type/research-summary" class="ng-do-media_item-type-link">Research Summary</a>
                </div>
                <h6 class="ng-do-media_item-title">
                    <a href="/do/10.1056/NEJMdo006348/full/" class="ng-do-media_item-title-link">Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis</a>
                </h6>
            </div>
        </div>
    </div>
    <div class="ng-page_separator mt-32"></div>
</div></div></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 1455 patients received tofacitinib at a dose of 5 mg twice daily, 1456 received tofacitinib at a dose of 10 mg twice daily, and 1451 received a TNF inhibitor. During a median follow-up of 4.0 years, the incidences of MACE and cancer were higher with the combined tofacitinib doses (3.4% [98 patients] and 4.2% [122 patients], respectively) than with a TNF inhibitor (2.5% [37 patients] and 2.9% [42 patients]). The hazard ratios were 1.33 (95% confidence interval [CI], 0.91 to 1.94) for MACE and 1.48 (95% CI, 1.04 to 2.09) for cancers; the noninferiority of tofacitinib was not shown. The incidences of adjudicated opportunistic infections (including herpes zoster and tuberculosis), all herpes zoster (nonserious and serious), and adjudicated nonmelanoma skin cancer were higher with tofacitinib than with a TNF inhibitor. Efficacy was similar in all three groups, with improvements from month 2 that were sustained through trial completion.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this trial comparing the combined tofacitinib doses with a TNF inhibitor in a cardiovascular risk–enriched population, risks of MACE and cancers were higher with tofacitinib and did not meet noninferiority criteria. Several adverse events were more common with tofacitinib. (Funded by Pfizer; ORAL Surveillance ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02092467" target="_blank">NCT02092467</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006347/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/9cebcb51-bf1b-41ef-b08e-a21b1319ed3d/media/NEJMdo006347_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006347/full/" class="ng-do-media_item-title-link">CV and Cancer Risk with Tofacitinib in RA</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 12s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Rheumatoid arthritis is a systemic, chronic, immune-mediated inflammatory disorder.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Treatments include conventional synthetic disease-modifying antirheumatic drugs (DMARDs); biologic DMARDs, such as tumor necrosis factor (TNF) inhibitors; and targeted synthetic DMARDs.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3" id="body-ref-r3" href-manipulated="true">2,3</a></sup> However, these drugs are associated with potentially serious adverse events.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6 r7 r8 r9 r10 r11" id="body-ref-r11" href-manipulated="true">4-11</a></sup></div><div role="paragraph">Tofacitinib is a targeted synthetic DMARD that selectively inhibits Janus kinase (JAK)1, JAK3, and, to a lesser extent, JAK2<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13" id="body-ref-r13" href-manipulated="true">12,13</a></sup> and is approved for the treatment of rheumatoid arthritis by the Food and Drug Administration (FDA) at doses of 5 mg twice daily or 11 mg once daily (extended-release formulation). During drug development, increases in serum lipid levels and the incidence of cancers, including lymphoma, were observed,<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15 r16" id="body-ref-r16" href-manipulated="true">14-16</a></sup> which prompted the FDA to require a prospective, head-to-head safety trial comparing tofacitinib with TNF inhibitors.</div><div role="paragraph">We report results from the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance, a randomized, postauthorization, noninferiority trial evaluating the safety and efficacy of tofacitinib as compared with a TNF inhibitor in patients with rheumatoid arthritis who were 50 years of age or older and had at least one additional cardiovascular risk factor. This noninferiority trial assessed the hypothesis that the risk of major adverse cardiovascular events (MACE) or cancers, excluding nonmelanoma skin cancer, would not be at least 1.8 times higher with tofacitinib (combined doses of 5 mg and 10 mg twice daily) than with a TNF inhibitor in this patient population.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">We enrolled patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor (current cigarette smoker, hypertension, high-density lipoprotein cholesterol level of &lt;40 mg per deciliter, diabetes mellitus, family history of premature coronary heart disease, extraarticular rheumatoid arthritis, or history of coronary artery disease). A key exclusion criteria was current or previous cancer, except adequately treated nonmelanoma skin cancer. Full eligibility criteria are provided in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.</div></section><section id="sec-1-2"><h3>Trial Design</h3><div role="paragraph">ORAL Surveillance was a randomized, open-label, noninferiority, phase 3b–4 safety end-point trial. Patients were randomly assigned in a 1:1:1 ratio, with the use of an automated Web and telephone system, to receive open-label oral tofacitinib at a dose of 5 mg or 10 mg twice daily or a subcutaneous TNF inhibitor (adalimumab at a dose of 40 mg every 2 weeks [in North America, including the United States, Puerto Rico, and Canada] or etanercept at a dose of 50 mg once weekly [in the rest of the world]); background methotrexate was continued, unless modification was clinically indicated. Details of concomitant rheumatoid arthritis medications are provided in the <a href="#ap2">Supplementary Appendix</a>. Patients could discontinue the trial drug for less than 2 months for safety issues. All the patients, including those who permanently discontinued the trial drug, were asked to continue to participate in the trial through its completion.</div><div role="paragraph">The first patient was enrolled in March 2014. In February 2019, the tofacitinib dose of 10 mg twice daily was reduced to 5 mg twice daily after the data and safety monitoring board noted a higher frequency of pulmonary embolism among patients receiving tofacitinib at a dose of 10 mg twice daily than among those receiving a TNF inhibitor. In addition, the board noted a higher mortality with tofacitinib at a dose of 10 mg twice daily than with tofacitinib at a dose of 5 mg twice daily or with a TNF inhibitor.</div></section><section id="sec-1-3"><h3>Trial Oversight</h3><div role="paragraph">The trial was conducted in compliance with the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonisation, and local regulations. Patients provided written, informed consent. The protocol, amendments, and consent documentation were approved by the institutional review board or independent ethics committee at each center. The <a href="#ap1">protocol</a> and statistical analysis plan are available at NEJM.org.</div><div role="paragraph">The trial was sponsored by Pfizer, which provided the trial medication. Sponsor employees and the academic authors designed the trial with the FDA. An external steering committee whose members were unaware of the trial-group assignments oversaw the conduct of the trial. An external data and safety monitoring board whose members were aware of the trial-group assignments provided recommendations on trial-conduct alterations to the steering committee and sponsor on the basis of ongoing safety monitoring. External committees adjudicated the coprimary end points and other adverse events of special interest (see the <a href="#ap2">Supplementary Appendix</a>). A contract research organization (ICON) collected the data, and sponsor employees and the academic authors analyzed and interpreted the data and vouch for its completeness and accuracy. The first draft of the manuscript was written by the academic authors without input from the sponsor or other writers. Editorial support was subsequently provided by CMC Connect and funded by Pfizer.</div></section><section id="sec-1-4"><h3>Trial End Points</h3><div role="paragraph">The coprimary end points were adjudicated MACE (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) and cancers, excluding nonmelanoma skin cancer. Secondary safety end points included adverse events of special interest (serious infections; adjudicated opportunistic infections, including herpes zoster and tuberculosis; all herpes zoster [nonserious and serious]; adjudicated hepatic events; adjudicated nonmelanoma skin cancer; adjudicated deaths from any cause; adjudicated venous thromboembolism, including deep-vein thrombosis and pulmonary embolism; all arterial thromboembolism; and adjudicated cardiovascular events other than MACE), all adverse events, serious adverse events, clinically significant laboratory abnormalities, adverse events leading to permanent or temporary discontinuations of a trial medication, serum lipid levels, and blood pressure levels. Additional adverse events of special interest included adjudicated interstitial lung disease and adjudicated gastrointestinal perforations.</div><div role="paragraph">Secondary efficacy end points and patient-reported outcomes, including the change from baseline in the Simplified Disease Activity Index (SDAI) score<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18 r19" id="body-ref-r19-1" href-manipulated="true">17-19</a></sup> and the Health Assessment Questionnaire–Disability Index (HAQ-DI) score<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> and the percentages of patients with SDAI-defined low disease activity (score of ≤11)<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-1" href-manipulated="true" aria-label="Reference 21">21</a></sup> and remission (score of ≤3.3),<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21-2" href-manipulated="true" aria-label="Reference 21">21</a></sup> were assessed at baseline and scheduled follow-up visits. All secondary efficacy end points and patient-reported outcomes are listed in the protocol. Adverse events were recorded on the adverse-event case-report form and presented according to the system organ class and preferred terms in the <i>Medical Dictionary for Regulatory Activities</i>, version 23.1. (For details on the trial end points, see the <a href="#ap2">Supplementary Appendix</a>.)</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We calculated that approximately 4000 patients, with 1500 or more patients completing 3 years of follow-up, were required to achieve the prespecified number of events: 103 MACE and 138 cancers to achieve 80% and 90% power, respectively, assuming that the rates were 1.0 and 1.1 events per 100 patient-years, respectively. (For details, see the <a href="#ap2">Supplementary Appendix</a>.) The estimated trial duration was 5 years.</div><div role="paragraph">Hazard ratios for each tofacitinib dose relative to a TNF inhibitor were estimated, with two-sided 95% confidence intervals, based on two Cox proportional-hazards models (for comparing the combined tofacitinib doses with a TNF inhibitor and for pairwise comparisons among treatment groups), with treatment as the covariate. Noninferiority would be shown if the upper limit of the two-sided 95% confidence interval for the hazard ratio was less than 1.8 for the combined tofacitinib doses as compared with a TNF inhibitor (primary comparison) or less than 2.0 for tofacitinib at a dose of 10 mg twice daily as compared with a dose of 5 mg twice daily (secondary comparison).<sup><a href="#core-r22" role="doc-biblioref" data-xml-rid="r22" id="body-ref-r22" href-manipulated="true" aria-label="Reference 22">22</a></sup> Crude incidence rates were expressed in patients with first events per 100 patient-years, with two-sided 95% confidence intervals.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> According to the protocol, no multiplicity adjustments were applied. P values, without adjustment for multiplicity, were produced for the coprimary end points (post hoc).</div><div role="paragraph">Safety end points were analyzed in the safety analysis population, which included all the patients who had undergone randomization and received at least one dose of a trial drug. Patients were analyzed in their originally assigned group, including those required to switch the tofacitinib dose from 10 mg twice daily to 5 mg twice daily in February 2019. In the group assigned to receive tofacitinib at a dose of 10 mg twice daily, the treatment period included the time after patients had been switched to 5 mg twice daily. For MACE, the primary censoring time was the 60-day on-treatment time, defined as the time from the first dose of a trial drug until the end of the risk period (i.e., last contact date or last trial dose plus 60 days, whichever was earliest). For cancers, the primary censoring time was total time, defined as the time from the first dose of a trial drug until the last contact date. The last contact date was the latest of the following: the start date of an adverse event, the end date of an adverse event, the date of the last trial visit, the withdrawal date, the telephone-contact date, or the date of death.</div><div role="paragraph">The number needed to harm was calculated post hoc for each tofacitinib dose. It was defined as the reciprocal of the difference in incidence rates between tofacitinib and a TNF inhibitor and interpreted as the number of patient-years of exposure to tofacitinib required to have one additional adverse event, relative to a TNF inhibitor.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24" href-manipulated="true" aria-label="Reference 24">24</a></sup> Additional details of secondary safety and efficacy end points, the efficacy population, subgroup analyses, supportive and sensitivity analyses for the coprimary end points (including analyses with data censored after patients had switched the tofacitinib dose from 10 mg twice daily to 5 mg twice daily in February 2019), and supportive analyses for the efficacy end points are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">The trial was conducted at 323 sites in 30 countries from March 2014 through July 2020. Of 6559 patients screened, 4362 underwent randomization and received a trial drug: 1455 received tofacitinib at a dose of 5 mg twice daily, 1456 received tofacitinib at a dose of 10 mg twice daily, and 1451 received a TNF inhibitor (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). Patients received tofacitinib at a dose of 5 mg or 10 mg twice daily or a TNF inhibitor for 5073.49, 4773.41, or 4940.72 patient-years, respectively, up to the last dose of a trial treatment, with a mean (±SD) duration of treatment of 41.14±17.48, 38.53±18.76, and 40.24±18.04 months (Table S1). The demographic and clinical characteristics of the patients at baseline were generally similar across trial groups (<a href="#t1">Table 1</a> and S2). At baseline, 31.0% of the patients were 65 years of age or older, the mean disease duration was more than 10 years, and 48.2% of the patients had ever smoked.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t1.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/47d6baaa-a021-4214-8baf-5bbcb7ce3fef/assets/images/large/nejmoa2109927_t1.jpg" height="1804" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Tofacitinib, 5 mg Twice Daily<br>(N=1455)</th><th class="txxx-borders">Tofacitinib, 10 mg Twice Daily<br>(N=1456)<a href="#t1fn2" role="doc-noteref">†</a></th><th class="txxx-borders">TNF Inhibitor<br>(N=1451)</th><th class="txxr-borders">Total<br>(N=4362)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">60.8±6.8</td><td class="xxxx-borders">61.4±7.1</td><td class="xxxx-borders">61.3±7.5</td><td class="xxxr-borders">61.2±7.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥65 yr — no. (%)</td><td class="xxxx-borders shading">413 (28.4)</td><td class="xxxx-borders shading">478 (32.8)</td><td class="xxxx-borders shading">462 (31.8)</td><td class="xxxr-borders shading">1353 (31.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">1169 (80.3)</td><td class="xxxx-borders">1124 (77.2)</td><td class="xxxx-borders">1117 (77.0)</td><td class="xxxr-borders">3410 (78.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">1128 (77.5)</td><td class="xxxx-borders">1126 (77.3)</td><td class="xxxx-borders">1099 (75.7)</td><td class="xxxr-borders">3353 (76.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">63 (4.3)</td><td class="xxxx-borders shading">65 (4.5)</td><td class="xxxx-borders shading">83 (5.7)</td><td class="xxxr-borders shading">211 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">65 (4.5)</td><td class="xxxx-borders">56 (3.8)</td><td class="xxxx-borders">55 (3.8)</td><td class="xxxr-borders">176 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">199 (13.7)</td><td class="xxxx-borders shading">209 (14.4)</td><td class="xxxx-borders shading">214 (14.7)</td><td class="xxxr-borders shading">622 (14.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Smoking status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Never smoked</td><td class="xxxx-borders shading">735 (50.5)</td><td class="xxxx-borders shading">752 (51.6)</td><td class="xxxx-borders shading">772 (53.2)</td><td class="xxxr-borders shading">2259 (51.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Ever smoked</td><td class="xxxx-borders">720 (49.5)</td><td class="xxxx-borders">704 (48.4)</td><td class="xxxx-borders">679 (46.8)</td><td class="xxxr-borders">2103 (48.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">History of hypertension — no. (%)</td><td class="xxxx-borders shading">955 (65.6)</td><td class="xxxx-borders shading">954 (65.5)</td><td class="xxxx-borders shading">969 (66.8)</td><td class="xxxr-borders shading">2878 (66.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">History of diabetes mellitus — no. (%)</td><td class="xxxx-borders">243 (16.7)</td><td class="xxxx-borders">261 (17.9)</td><td class="xxxx-borders">255 (17.6)</td><td class="xxxr-borders">759 (17.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">History of venous thromboembolism — no. (%)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">19 (1.3)</td><td class="xxxx-borders shading">33 (2.3)</td><td class="xxxx-borders shading">27 (1.9)</td><td class="xxxr-borders shading">79 (1.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">History of extraarticular disease — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">532 (36.6)</td><td class="xxxx-borders">521 (35.8)</td><td class="xxxx-borders">552 (38.0)</td><td class="xxxr-borders">1605 (36.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">History of coronary heart disease — no. (%)</td><td class="xxxx-borders shading">161 (11.1)</td><td class="xxxx-borders shading">172 (11.8)</td><td class="xxxx-borders shading">164 (11.3)</td><td class="xxxr-borders shading">497 (11.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Family history of coronary heart disease — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">First-degree male relative &lt;55 yr of age</td><td class="xxxx-borders shading">154 (10.6)</td><td class="xxxx-borders shading">132 (9.1)</td><td class="xxxx-borders shading">151 (10.4)</td><td class="xxxr-borders shading">437 (10.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">First-degree female relative &lt;65 yr of age</td><td class="xxxx-borders">115 (7.9)</td><td class="xxxx-borders">107 (7.3)</td><td class="xxxx-borders">100 (6.9)</td><td class="xxxr-borders">322 (7.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Fasting HDL cholesterol &lt;40 mg/dl — no. (%)</td><td class="xbxx-borders shading">172 (11.8)</td><td class="xbxx-borders shading">195 (13.4)</td><td class="xbxx-borders shading">173 (11.9)</td><td class="xbxr-borders shading">540 (12.4)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Safety Analysis Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. HDL denotes high-density lipoprotein, and TNF tumor necrosis factor.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily or who discontinued the trial drug were counted in the group receiving 10 mg twice daily.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Venous thromboembolism included deep-vein thrombosis and pulmonary embolism.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Extraarticular disease included nodules, Sjögren’s syndrome, anemia of chronic disease, pulmonary manifestations, or other clinical features as identified by the site investigator.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Primary End Points</h3><section id="sec-2-2-1"><h4>Adjudicated MACE</h4><div role="paragraph">During a median follow-up of 4.0 years, the incidence of MACE was higher with the combined tofacitinib doses (3.4%; 98 patients) than with a TNF inhibitor (2.5%; 37 patients). Noninferiority was not shown for the combined tofacitinib doses as compared with a TNF inhibitor (hazard ratio, 1.33; 95% confidence interval [CI], 0.91 to 1.94), because the upper boundary of the 95% confidence interval was more than 1.8 (<a href="#f1">Figure 1A</a>). In comparisons between tofacitinib doses, noninferiority was shown for tofacitinib at a dose of 10 mg twice daily as compared with 5 mg twice daily (hazard ratio, 1.15; 95% CI, 0.77 to 1.71), because the upper boundary of the 95% confidence interval was less than 2.0. MACE incidence rates are reported in <a href="#f1">Figure 1B</a>. Per-protocol analyses and analyses that accounted for competing risks supported the findings of the primary and secondary comparisons (Fig. S2A and S2B and Table S3). Sensitivity analyses with follow-up censored after patients receiving tofacitinib at a dose of 10 mg twice daily had been switched to 5 mg twice daily supported the findings of the primary comparison, and noninferiority was not shown for tofacitinib at a dose of 10 mg twice daily as compared with 5 mg twice daily (Fig. S3A and S3B). The most common cases of MACE were nonfatal myocardial infarction with tofacitinib and nonfatal stroke with a TNF inhibitor.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f1.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/95d72be3-9229-47bb-aef1-86930d215152/assets/images/large/nejmoa2109927_f1.jpg" height="1958" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Hazard Ratios and Incidence Rates for Adjudicated MACE (Safety Analysis Population, 60-Day On-Treatment Time).</div><div class="notes"><div role="doc-footnote">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. The number needed to harm (NNH) was the number of patient-years of exposure to tofacitinib required to have one additional major adverse cardiovascular event (MACE), relative to a tumor necrosis factor (TNF) inhibitor; calculations were performed post hoc. The NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than with a TNF inhibitor to result in one additional MACE; calculations were performed post hoc. P values for the testing of the null hypotheses of no difference between treatments were for hypothesis generation and descriptive purposes only (post hoc). The P values were 0.14 for the combined tofacitinib doses as compared with a TNF inhibitor, 0.48 for tofacitinib at a dose of 10 mg twice daily as compared with tofacitinib at a dose of 5 mg twice daily, 0.33 for tofacitinib at a dose of 5 mg twice daily as compared with a TNF inhibitor, and 0.10 for tofacitinib at a dose of 10 mg twice daily as compared with a TNF inhibitor. The 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure></div><div role="paragraph">Over a period of 5.5 years, the cumulative estimated probability of MACE was 5.8% with the combined tofacitinib doses and 4.3% with a TNF inhibitor (Fig. S4A). The cumulative estimated probability of nonfatal myocardial infarction was 2.2% and 0.7%, respectively (Fig. S4B).</div><div role="paragraph">In subgroup analyses, the incidence rates of MACE were higher across trial groups among patients 65 years of age or older than among those younger than 65 years of age and higher with both tofacitinib doses than with a TNF inhibitor among patients 65 years of age or older (Fig. S5A and S5B). Incidence rates were also higher among patients in North America than among those in the rest of the world across trial groups (Fig. S5C and S5D), which possibly corresponded with increased risk factors among patients in North America (Table S4).</div></section><section id="sec-2-2-2"><h4>Adjudicated Cancers</h4><div role="paragraph">During a median follow-up of 4.0 years, the incidence of cancers (excluding nonmelanoma skin cancer) was higher with the combined tofacitinib doses (4.2%; 122 patients) than with a TNF inhibitor (2.9%; 42 patients). Noninferiority was not shown for the combined tofacitinib doses as compared with a TNF inhibitor (hazard ratio, 1.48; 95% CI, 1.04 to 2.09), because the upper boundary of the 95% confidence interval was more than 1.8 (<a href="#f2">Figure 2A</a>). In comparisons between tofacitinib doses, noninferiority was shown for 10 mg twice daily as compared with 5 mg twice daily (hazard ratio, 1.00; 95% CI, 0.70 to 1.43), because the upper boundary of the 95% confidence interval was less than 2.0. Incidence rates of cancers are shown in <a href="#f2">Figure 2B</a>. Per-protocol, competing-risk, and censoring sensitivity analyses supported the finding of the primary and secondary comparisons (Fig. S2C and S2D, Fig. S3C and S3D, and Table S3). The most common cancers were lung cancer with tofacitinib and breast cancer with a TNF inhibitor.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f2.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/8ee92f74-9d41-4241-94d0-c77182f5a005/assets/images/large/nejmoa2109927_f2.jpg" height="1958" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Hazard Ratios and Incidence Rates for Adjudicated Cancers, Excluding NMSC (Safety Analysis Population, Total-Time Analysis).</div><div class="notes"><div role="doc-footnote">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. The NNH was the number of patient-years of exposure to tofacitinib required to have one additional cancer, relative to a TNF inhibitor; calculations were performed post hoc. The NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than with a TNF inhibitor to result in one additional cancer; calculations were performed post hoc. P values for the testing of the null hypotheses of no difference between treatments were for hypothesis generation and descriptive purposes only (post hoc). The P values were 0.03 for the combined tofacitinib doses as compared with a TNF inhibitor, 0.99 for tofacitinib at a dose of 10 mg twice daily as compared with tofacitinib at a dose of 5 mg twice daily, 0.05 for tofacitinib at a dose of 5 mg twice daily as compared with a TNF inhibitor, and 0.05 for tofacitinib at a dose of 10 mg twice daily as compared with a TNF inhibitor. The 𝙸 bars represent 95% confidence intervals. NMSC denotes nonmelanoma skin cancer.</div></div></figcaption></figure></div><div role="paragraph">Over a period of 5.5 years, the estimated cumulative probability of cancers was 6.1% with the combined tofacitinib doses and 3.8% with a TNF inhibitor (Fig. S4C). The incidence rates of cancer were higher among patients 65 years of age or older than among those younger than 65 years of age and higher among those in North America than among those in the rest of the world (Fig. S6). The incidence rate was higher with tofacitinib than with a TNF inhibitor in North America.</div></section></section><section id="sec-2-3"><h3>Secondary Safety End Points</h3><div role="paragraph">The most frequent adverse events and serious adverse events that emerged or worsened during treatment according to system organ class were infections and infestations. Upper respiratory tract infections, bronchitis, and urinary tract infections were the most common adverse events, and pneumonia the most common serious adverse event, across trial groups (Tables S5 and S6). Clinical laboratory abnormalities are described in the <a href="#ap2">Supplementary Appendix</a>, including in Table S7. Serious adverse events and temporary or permanent discontinuations of a trial treatment due to adverse events are shown in <a href="#t2">Table 2</a>. Adverse events (according to system organ class) leading to permanent discontinuation of a trial treatment are shown in Table S8.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t2.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/03b51f31-5f31-4c4b-81b1-d318b1a475d5/assets/images/large/nejmoa2109927_t2.jpg" height="2015" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Tofacitinib, 5 mg Twice Daily<br>(N=1455)</th><th class="txxx-borders">Tofacitinib, 10 mg Twice Daily<br>(N=1456)<a href="#t2fn2" role="doc-noteref">†</a></th><th class="txxr-borders">TNF Inhibitor<br>(N=1451)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event — no. (%)</td><td class="xxxx-borders shading">1333 (91.6)</td><td class="xxxx-borders shading">1344 (92.3)</td><td class="xxxr-borders shading">1308 (90.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders">351 (24.1)</td><td class="xxxx-borders">390 (26.8)</td><td class="xxxr-borders">306 (21.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Discontinuation of trial treatment due to adverse event — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Permanent discontinuation<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">210 (14.4)</td><td class="xxxx-borders">304 (20.9)</td><td class="xxxr-borders">210 (14.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Temporary discontinuation<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">665 (45.7)</td><td class="xxxx-borders shading">736 (50.5)</td><td class="xxxr-borders shading">576 (39.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Adverse events of special interest</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious infection — no. (%)</td><td class="xxxx-borders shading">141 (9.7)</td><td class="xxxx-borders shading">169 (11.6)</td><td class="xxxr-borders shading">119 (8.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.17 (0.92–1.50)</td><td class="xxxx-borders">1.48 (1.17–1.87)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated opportunistic infection — no. (%)<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">39 (2.7)</td><td class="xxxx-borders shading">44 (3.0)</td><td class="xxxr-borders shading">21 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.82 (1.07–3.09)</td><td class="xxxx-borders">2.17 (1.29–3.66)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">All herpes zoster, serious and nonserious — no. (%)<a href="#t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">180 (12.4)</td><td class="xxxx-borders shading">178 (12.2)</td><td class="xxxr-borders shading">58 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">3.28 (2.44–4.41)</td><td class="xxxx-borders">3.39 (2.52–4.55)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated hepatic event — no. (%)</td><td class="xxxx-borders shading">46 (3.2)</td><td class="xxxx-borders shading">72 (4.9)</td><td class="xxxr-borders shading">35 (2.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.29 (0.83–2.00)</td><td class="xxxx-borders">2.14 (1.43–3.21)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated NMSC — no. (%)</td><td class="xxxx-borders shading">31 (2.1)</td><td class="xxxx-borders shading">33 (2.3)</td><td class="xxxr-borders shading">16 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.90 (1.04–3.47)</td><td class="xxxx-borders">2.16 (1.19–3.92)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated pulmonary embolism — no. (%)</td><td class="xxxx-borders shading">9 (0.6)</td><td class="xxxx-borders shading">24 (1.6)</td><td class="xxxr-borders shading">3 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">2.93 (0.79–10.83)</td><td class="xxxx-borders">8.26 (2.49–27.43)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated DVT — no. (%)</td><td class="xxxx-borders shading">11 (0.8)</td><td class="xxxx-borders shading">15 (1.0)</td><td class="xxxr-borders shading">7 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.54 (0.60–3.97)</td><td class="xxxx-borders">2.21 (0.90–5.43)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated VTE — no. (%)</td><td class="xxxx-borders shading">17 (1.2)</td><td class="xxxx-borders shading">34 (2.3)</td><td class="xxxr-borders shading">10 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.66 (0.76–3.63)</td><td class="xxxx-borders">3.52 (1.74–7.12)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated death from any cause — no. (%)</td><td class="xxxx-borders shading">26 (1.8)</td><td class="xxxx-borders shading">39 (2.7)</td><td class="xxxr-borders shading">17 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xbxx-borders">1.49 (0.81–2.74)</td><td class="xbxx-borders">2.37 (1.34–4.18)</td><td class="xbxr-borders">Referent</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events (Safety Analysis Population, 28-Day On-Treatment Time).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Shown are adverse events that emerged or worsened during the 28-day on-treatment period, which was defined as the minimum of the date of last contact or the date of the last dose of a trial treatment plus 28 days. DVT denotes deep-vein thrombosis, NMSC nonmelanoma skin cancer, and VTE venous thromboembolism.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Data are based on the adverse-event and disposition case-report forms.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">At the discretion of the investigator, discontinuations of trial medication were allowed, not to exceed 2 months, for safety issues.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Also included are opportunistic herpes zoster and tuberculosis events.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">Included are herpes zoster adjudicated as an opportunistic infection and nonadjudicated herpes zoster events.</div></div></div></figcaption></figure></div><div role="paragraph">Hazard ratios and incidence rates for adverse events of special interest and additional adverse events of interest are shown in <a href="#t2">Table 2</a>, S9, and S10. Serious infections were more frequent with tofacitinib at a dose of 10 mg twice daily than with a TNF inhibitor. Adjudicated opportunistic infections (including herpes zoster and tuberculosis) were more frequent with both tofacitinib doses than with a TNF inhibitor, primarily owing to the incidence of herpes zoster. All herpes zoster (nonserious and serious) and adjudicated herpes zoster were also more frequent with both tofacitinib doses than with a TNF inhibitor. Additional details about herpes zoster cases are provided in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">Adjudicated hepatic events were more frequent with tofacitinib at a dose of 10 mg twice daily than with a TNF inhibitor, primarily owing to greater abnormalities on liver-function tests with tofacitinib than with a TNF inhibitor (<a href="#t2">Table 2</a> and S11). No events were adjudicated as being definite or highly likely cases of drug-induced liver injury.</div><div role="paragraph">Adjudicated nonmelanoma skin cancer was more frequent with both tofacitinib doses than with a TNF inhibitor. Adjudicated venous thromboembolism and death from any cause were more frequent with tofacitinib at a dose of 10 mg twice daily than with a TNF inhibitor. Hazard ratios for adjudicated pulmonary embolism were more than 1, but 95% confidence intervals were wide. The main cause of adjudicated death across trial groups was cardiovascular events (Table S12).</div><div role="paragraph">Adverse events of special interest were generally similar between tofacitinib doses, except for serious infections, adjudicated hepatic events, pulmonary embolism, and venous thromboembolism, which were more frequent with 10 mg twice daily. Serum lipid levels were higher with both tofacitinib doses than with a TNF inhibitor through trial completion (Figs. S7 and S8); blood pressure values were generally similar across trial groups (Fig. S9).</div></section><section id="sec-2-4"><h3>Efficacy End Points and Patient-Reported Outcomes</h3><div role="paragraph">Efficacy was similar across treatments, with decreases (improvements) in the SDAI score and the HAQ-DI score and increases in the incidence of SDAI-defined low disease activity and remission observed from month 2 (first postbaseline assessment) and sustained through trial completion (<a href="#f3">Figure 3</a> and S10). Post hoc supportive analyses that accounted for missing values yielded similar results for the incidence of SDAI-defined low disease activity and remission (Fig. S11). Similar improvements were observed for all other efficacy end points and patient-reported outcomes (data not shown).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f3.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/8fcc68a3-8f70-4f6d-8d13-e7cc80a5f37b/assets/images/large/nejmoa2109927_f3.jpg" height="1698" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Least-Squares Mean Change from Baseline in SDAI Score (Full Analysis Population, On-Treatment Time).</div><div class="notes"><div role="doc-footnote">Simplified Disease Activity Index (SDAI) scores range from 0 to 100, with higher scores indicating more disease activity.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18 r19" id="body-ref-r19-2" href-manipulated="true">17-19</a></sup> For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. Data were derived from a mixed model for repeated measures, with fixed effects for trial group, visit, interaction between trial group and visit, baseline value, and interaction between baseline value and visit, without imputation for missing values. A common heterogeneous compound symmetry covariance matrix was used. The 95% confidence intervals (indicated by 𝙸 bars) for all efficacy data were not adjusted for multiplicity and therefore should not be used to infer treatment effects. On-treatment time includes data on or before the trial treatment end date. Only visits with more than 50 patients for each treatment group were included.</div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">MACE and cancers occurred more often with tofacitinib than with a TNF inhibitor in this trial that included patients with rheumatoid arthritis who were 50 years of age or older and had at least one additional cardiovascular risk factor. For MACE and cancers (coprimary end points), noninferiority was not shown for the combined tofacitinib doses as compared with a TNF inhibitor. Adjudicated opportunistic infections (including herpes zoster), all herpes zoster (nonserious and serious), and adjudicated nonmelanoma skin cancer occurred more often with both tofacitinib doses than with a TNF inhibitor. The incidences of death from any cause and of pulmonary embolism were higher with tofacitinib at a dose of 10 mg twice daily than with a TNF inhibitor, which led to the switch in the tofacitinib dose from 10 twice daily to 5 mg twice daily during the trial.</div><div role="paragraph">In terms of age and sex, patients in our trial were generally representative of the broader population of patients participating in rheumatoid arthritis trials (Tables S4 and S13), with underrepresentation of Black patients with rheumatoid arthritis, as has been observed for other trials.<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> In prespecified subgroup analyses, differences in the risk of MACE and cancers between tofacitinib and a TNF inhibitor were more pronounced in patients 65 years of age or older than in younger patients.</div><div role="paragraph">Patients with rheumatoid arthritis are at higher risk for MACE and cancers than are persons in the general population.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="body-ref-r27" href-manipulated="true">26,27</a></sup> For MACE, this may be due to systemic inflammation and traditional risk factors,<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> whereas for cancers, potential factors include chronic inflammation, common environmental and genetic factors between cancer and rheumatoid arthritis, or immunosuppressive treatments for rheumatoid arthritis.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup> In patients without rheumatoid arthritis who have a high inflammatory risk, targeting inflammation has been shown to reduce the incidence of cardiovascular events; similarly, TNF inhibitors appear to decrease the risk of cardiovascular events among patients with rheumatoid arthritis.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30 r31" id="body-ref-r31" href-manipulated="true">30,31</a></sup> This trial showed increased lipid levels with tofacitinib, which are caused by reduced cholesterol ester catabolism<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14-2" href-manipulated="true" aria-label="Reference 14">14</a></sup> that has not previously been associated with an increased risk of MACE.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup> Because there were no other control groups in ORAL Surveillance, the incidences of MACE and cancers could not be compared with the incidences with conventional synthetic DMARDs, other biologic DMARDs, or no treatment.</div><div role="paragraph">Efficacy was similar across trial groups, with improvements from month 2 and sustained through trial completion, findings that raise the question of the risk–benefit assessment. In this trial, the number needed to harm for tofacitinib at a dose of 5 mg twice daily (FDA-approved dose for rheumatoid arthritis) relative to a TNF inhibitor was 567 patient-years for MACE and 276 patient-years for cancers, which meant that during 5 years of treatment, 113 and 55 patients would need to be treated with tofacitinib at a dose of 5 mg twice daily rather than with a TNF inhibitor to result in one additional MACE and cancer, respectively.</div><div role="paragraph">Strengths of this trial included a large patient cohort followed for up to 6 years, with 16,448 patient-years of exposure; up to 50% of the patients across treatments were followed for at least 48 months. These data provide a better understanding of the safety and efficacy of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis who are 50 years of age or older and have at least one additional cardiovascular risk factor.</div><div role="paragraph">Limitations of the trial include the open-label design, high rates of discontinuation of trial treatment, a lack of other control groups, and the use of adalimumab in North America and etanercept in the rest of the world. This trial was not powered to compare the risk of venous thromboembolism across treatments. It is also unclear whether the risks are specific to this patient population and to tofacitinib as compared with other JAK inhibitors and whether the relative risk differed between adalimumab and etanercept. Analyses were not adjusted for multiple comparisons.</div><div role="paragraph">Taken together, these results show the higher risk of MACE and cancers with tofacitinib than with TNF inhibitors. The efficacies of tofacitinib and TNF inhibitors were similar across multiple outcomes.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Pfizer</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank Jennifer Arnold, Ph.D., and Anthony G. McCluskey, Ph.D., of CMC Connect, McCann Health Medical Communications, for medical writing support.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2109927_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2109927/suppl_file/nejmoa2109927_protocol.pdf" download="nejmoa2109927_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2109927_protocol.pdf" data-doi="10.1056/NEJMoa2109927">Download</a></li><li>9.31 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2109927_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2109927/suppl_file/nejmoa2109927_appendix.pdf" download="nejmoa2109927_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2109927_appendix.pdf" data-doi="10.1056/NEJMoa2109927">Download</a></li><li>3.47 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2109927_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2109927/suppl_file/nejmoa2109927_disclosures.pdf" download="nejmoa2109927_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2109927_disclosures.pdf" data-doi="10.1056/NEJMoa2109927">Download</a></li><li>676.76 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2109927_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2109927/suppl_file/nejmoa2109927_data-sharing.pdf" download="nejmoa2109927_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2109927_data-sharing.pdf" data-doi="10.1056/NEJMoa2109927">Download</a></li><li>71.73 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. <em>Lancet</em> 2010;376:1094-1108.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(10)60826-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20870100/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282411600037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rheumatoid+arthritis.&amp;publication_year=2010&amp;journal=Lancet&amp;pages=1094-1108&amp;doi=10.1016%2FS0140-6736%2810%2960826-4&amp;pmid=20870100" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <em>Arthritis Rheumatol</em> 2021;73:1108-1123.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41752" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34101376/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2021+American+College+of+Rheumatology+guideline+for+the+treatment+of+rheumatoid+arthritis.&amp;publication_year=2021&amp;journal=Arthritis+Rheumatol&amp;pages=1108-1123&amp;doi=10.1002%2Fart.41752&amp;pmid=34101376" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <em>Ann Rheum Dis</em> 2020;79:685-699.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2019-216655" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31969328/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000557252600024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EULAR+recommendations+for+the+management+of+rheumatoid+arthritis+with+synthetic+and+biological+disease-modifying+antirheumatic+drugs%3A+2019+update.&amp;publication_year=2020&amp;journal=Ann+Rheum+Dis&amp;pages=685-699&amp;doi=10.1136%2Fannrheumdis-2019-216655&amp;pmid=31969328" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. <em>Lancet</em> 2015;386:258-265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)61704-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25975452/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358213700030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+serious+infection+in+biological+treatment+of+patients+with+rheumatoid+arthritis%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2015&amp;journal=Lancet&amp;pages=258-265&amp;doi=10.1016%2FS0140-6736%2814%2961704-9&amp;pmid=25975452" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <em>Rheumatology (Oxford)</em> 2019;58:1755-1766.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/kez087" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30982883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491255500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+systematic+review+and+meta-analysis+of+infection+risk+with+small+molecule+JAK+inhibitors+in+rheumatoid+arthritis.&amp;publication_year=2019&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1755-1766&amp;doi=10.1093%2Frheumatology%2Fkez087&amp;pmid=30982883" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. <em>Arthritis Rheum</em> 1996;39:723-731.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.1780390503" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8639168/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+monitoring+drug+therapy+in+rheumatoid+arthritis.&amp;publication_year=1996&amp;journal=Arthritis+Rheum&amp;pages=723-731&amp;doi=10.1002%2Fart.1780390503&amp;pmid=8639168" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. <em>Ann Intern Med</em> 2020;172:369-380.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M19-3369" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32066146/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000520170800023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adverse+effects+of+low-dose+methotrexate%3A+a+randomized+trial.&amp;publication_year=2020&amp;journal=Ann+Intern+Med&amp;pages=369-380&amp;doi=10.7326%2FM19-3369&amp;pmid=32066146" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. <em>Semin Arthritis Rheum</em> 2020;50:930-937.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.semarthrit.2020.08.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32906027/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000580602000022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+malignancy+with+non-TNFi+biologic+or+tofacitinib+therapy+in+rheumatoid+arthritis%3A+a+meta-analysis+of+observational+studies.&amp;publication_year=2020&amp;journal=Semin+Arthritis+Rheum&amp;pages=930-937&amp;doi=10.1016%2Fj.semarthrit.2020.08.007&amp;pmid=32906027" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Kremer JM, Bingham CO III, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. <em>ACR Open Rheumatol</em> 2021;3:173-184.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr2.11232" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33570260/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Postapproval+comparative+safety+study+of+tofacitinib+and+biological+disease-modifying+antirheumatic+drugs%3A+5-year+results+from+a+United+States-based+rheumatoid+arthritis+registry.&amp;publication_year=2021&amp;journal=ACR+Open+Rheumatol&amp;pages=173-184&amp;doi=10.1002%2Facr2.11232&amp;pmid=33570260" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. <em>Joint Bone Spine</em> 2017;84:133-140.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jbspin.2016.02.028" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27341745/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396444100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+of+biologic+DMARDs+in+RA+patients+in+real+life%3A+a+systematic+literature+review+and+meta-analyses+of+biologic+registers.&amp;publication_year=2017&amp;journal=Joint+Bone+Spine&amp;pages=133-140&amp;doi=10.1016%2Fj.jbspin.2016.02.028&amp;pmid=27341745" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Singh S, Fumery M, Singh AG, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. <em>Arthritis Care Res (Hoboken)</em> 2020;72:561-576.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.23875" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30875456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521664600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+risk+of+cardiovascular+events+with+biologic+and+synthetic+disease-modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2020&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=561-576&amp;doi=10.1002%2Facr.23875&amp;pmid=30875456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). <em>J Immunol</em> 2011;186:4234-4243.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1003668" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21383241/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000288751200048" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Modulation+of+innate+and+adaptive+immune+responses+by+tofacitinib+%28CP-690%2C550%29.&amp;publication_year=2011&amp;journal=J+Immunol&amp;pages=4234-4243&amp;doi=10.4049%2Fjimmunol.1003668&amp;pmid=21383241" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. <em>J Inflamm (Lond)</em> 2010;7:41-41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1476-9255-7-41" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20701804/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282350100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis.&amp;publication_year=2010&amp;journal=J+Inflamm+%28Lond%29&amp;pages=41-41&amp;doi=10.1186%2F1476-9255-7-41&amp;pmid=20701804" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. <em>Arthritis Rheumatol</em> 2015;67:616-625.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.38974" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25470338/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Potential+mechanisms+leading+to+the+abnormal+lipid+profile+in+patients+with+rheumatoid+arthritis+versus+healthy+volunteers+and+reversal+by+tofacitinib.&amp;publication_year=2015&amp;journal=Arthritis+Rheumatol&amp;pages=616-625&amp;doi=10.1002%2Fart.38974&amp;pmid=25470338" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cancers, including lymphoma, were observed, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by reduced cholesterol ester catabolism </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. <em>Semin Arthritis Rheum</em> 2016;46:71-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.semarthrit.2016.03.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27079757/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000381447200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+tofacitinib+and+other+DMARDs+on+lipid+profiles+in+rheumatoid+arthritis%3A+implications+for+the+rheumatologist.&amp;publication_year=2016&amp;journal=Semin+Arthritis+Rheum&amp;pages=71-80&amp;doi=10.1016%2Fj.semarthrit.2016.03.004&amp;pmid=27079757" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content"><em>Xeljanz (tofacitinib): highlights of prescribing information</em>. New York: Pfizer, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Xeljanz+%28tofacitinib%29%3A+highlights+of+prescribing+information&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. <em>Rheumatology (Oxford)</em> 2003;42:244-257.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keg072" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12595618/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000181378100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+simplified+disease+activity+index+for+rheumatoid+arthritis+for+use+in+clinical+practice.&amp;publication_year=2003&amp;journal=Rheumatology+%28Oxford%29&amp;pages=244-257&amp;doi=10.1093%2Frheumatology%2Fkeg072&amp;pmid=12595618" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Disease Activity Index (SDAI) score </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r17-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score with ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). <em>Arthritis Care Res (Hoboken)</em> 2011;63:Suppl 11:S14-S36.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20621" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22588741/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297219500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measures+of+rheumatoid+arthritis+disease+activity%3A+Patient+%28PtGA%29+and+Provider+%28PrGA%29+Global+Assessment+of+Disease+Activity%2C+Disease+Activity+Score+%28DAS%29+and+Disease+Activity+Score+with+28-Joint+Counts+%28DAS28%29%2C+Simplified+Disease+Activity+Index+%28SDAI%29%2C+Clinical+Disease+Activity+Index+%28CDAI%29%2C+Patient+Activity+Score+%28PAS%29+and+Patient+Activity+Score-II+%28PASII%29%2C+Routine+Assessment+of+Patient+Index+Data+%28RAPID%29%2C+Rheumatoid+Arthritis+Disease+Activity+Index+%28RADAI%29+and+Rheumatoid+Arthritis+Disease+Activity+Index-5+%28RADAI-5%29%2C+Chronic+Arthritis+Systemic+Index+%28CASI%29%2C+Patient-Based+Disease+Activity+Score+with+ESR+%28PDAS1%29+and+Patient-Based+Disease+Activity+Score+without+ESR+%28PDAS2%29%2C+and+Mean+Overall+Index+for+Rheumatoid+Arthritis+%28MOI-RA%29.&amp;publication_year=2011&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=S14-S36&amp;doi=10.1002%2Facr.20621&amp;pmid=22588741" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Disease Activity Index (SDAI) score </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r18-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Aletaha D. Scores for all seasons: SDAI and CDAI. <em>Clin Exp Rheumatol</em> 2014;32:Suppl 85:S-75–S-79.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25365093/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000344721300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Scores+for+all+seasons%3A+SDAI+and+CDAI.&amp;publication_year=2014&amp;journal=Clin+Exp+Rheumatol&amp;pages=S-75-S-79&amp;pmid=25365093" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Disease Activity Index (SDAI) score </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r19-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). <em>Arthritis Care Res (Hoboken)</em> 2011;63:Suppl 11:S4-S13.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20620" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22588760/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297219500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measures+of+functional+status+and+quality+of+life+in+rheumatoid+arthritis%3A+Health+Assessment+Questionnaire+Disability+Index+%28HAQ%29%2C+Modified+Health+Assessment+Questionnaire+%28MHAQ%29%2C+Multidimensional+Health+Assessment+Questionnaire+%28MDHAQ%29%2C+Health+Assessment+Questionnaire+II+%28HAQ-II%29%2C+Improved+Health+Assessment+Questionnaire+%28Improved+HAQ%29%2C+and+Rheumatoid+Arthritis+Quality+of+Life+%28RAQoL%29.&amp;publication_year=2011&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=S4-S13&amp;doi=10.1002%2Facr.20620&amp;pmid=22588760" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. <em>Arthritis Rheum</em> 2005;52:2625-2636.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.21235" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16142705/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remission+and+active+disease+in+rheumatoid+arthritis%3A+defining+criteria+for+disease+activity+states.&amp;publication_year=2005&amp;journal=Arthritis+Rheum&amp;pages=2625-2636&amp;doi=10.1002%2Fart.21235&amp;pmid=16142705" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] low disease activity (score of ≤11) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and remission (score of ≤3.3), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Guidance for industry. 2008 (<a href="https://www.fda.gov/media/71297/download">https://www.fda.gov/media/71297/download</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diabetes+mellitus+%E2%80%94+evaluating+cardiovascular+risk+in+new+antidiabetic+therapies+to+treat+type+2+diabetes.+Guidance+for+industry&amp;publication_year=2008" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. <em>Comput Biol Med</em> 1992;22:351-361.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0010-4825(92)90023-G" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1424580/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JU25200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Simple+SAS+macros+for+the+calculation+of+exact+binomial+and+Poisson+confidence+limits.&amp;publication_year=1992&amp;journal=Comput+Biol+Med&amp;pages=351-361&amp;doi=10.1016%2F0010-4825%2892%2990023-G&amp;pmid=1424580" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy — report of the ISPOR risk-benefit management working group. <em>Value Health</em> 2010;13:657-666.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1524-4733.2010.00725.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20412543/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280674200020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+review+of+quantitative+risk-benefit+methodologies+for+assessing+drug+safety+and+efficacy+%E2%80%94+report+of+the+ISPOR+risk-benefit+management+working+group.&amp;publication_year=2010&amp;journal=Value+Health&amp;pages=657-666&amp;doi=10.1111%2Fj.1524-4733.2010.00725.x&amp;pmid=20412543" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Strait A, Castillo F, Choden S, et al. Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: a systematic review. <em>JAMA Netw Open</em> 2019;2(11):e1914745-e1914745.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamanetworkopen.2019.14745" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31722023/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505224400030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Demographic+characteristics+of+participants+in+rheumatoid+arthritis+randomized+clinical+trials%3A+a+systematic+review.&amp;publication_year=2019&amp;journal=JAMA+Netw+Open&amp;pages=e1914745-e1914745&amp;doi=10.1001%2Fjamanetworkopen.2019.14745&amp;pmid=31722023" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Aviña-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. <em>Ann Rheum Dis</em> 2012;71:1524-1529.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2011-200726" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22425941/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000307646500016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+incident+cardiovascular+events+in+patients+with+rheumatoid+arthritis%3A+a+meta-analysis+of+observational+studies.&amp;publication_year=2012&amp;journal=Ann+Rheum+Dis&amp;pages=1524-1529&amp;doi=10.1136%2Fannrheumdis-2011-200726&amp;pmid=22425941" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. <em>Arthritis Res Ther</em> 2015;17:212-212.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13075-015-0728-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26271620/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359526300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+malignancy+in+adult+patients+with+rheumatoid+arthritis%3A+a+meta-analysis.&amp;publication_year=2015&amp;journal=Arthritis+Res+Ther&amp;pages=212-212&amp;doi=10.1186%2Fs13075-015-0728-9&amp;pmid=26271620" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. <em>Ann Rheum Dis</em> 2011;70:8-14.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/ard.2010.142133" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21109513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285381100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cardiovascular+disease+in+rheumatoid+arthritis%3A+state+of+the+art+and+future+perspectives.&amp;publication_year=2011&amp;journal=Ann+Rheum+Dis&amp;pages=8-14&amp;doi=10.1136%2Fard.2010.142133&amp;pmid=21109513" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Szekanecz Z, Szekanecz E, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases — a mini-review. <em>Gerontology</em> 2011;57:3-10.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000314634" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20453490/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285580900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Malignancies+in+autoimmune+rheumatic+diseases+%E2%80%94+a+mini-review.&amp;publication_year=2011&amp;journal=Gerontology&amp;pages=3-10&amp;doi=10.1159%2F000314634&amp;pmid=20453490" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. <em>N Engl J Med</em> 2017;377:1119-1131.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_31_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2109927&amp;key=10.1056%2FNEJMoa1707914&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28845751/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411348500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antiinflammatory+therapy+with+canakinumab+for+atherosclerotic+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1119-1131&amp;doi=10.1056%2FNEJMoa1707914&amp;pmid=28845751" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Barnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. <em>Arthritis Care Res (Hoboken)</em> 2011;63:522-529.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20371" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20957658/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000289422700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+review+and+meta-analysis%3A+anti-tumor+necrosis+factor+%CE%B1+therapy+and+cardiovascular+events+in+rheumatoid+arthritis.&amp;publication_year=2011&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=522-529&amp;doi=10.1002%2Facr.20371&amp;pmid=20957658" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. <em>Arthritis Rheumatol</em> 2019;71:1450-1459.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40911" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31385441/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+factors+for+major+adverse+cardiovascular+events+in+phase+III+and+long-term+extension+studies+of+tofacitinib+in+patients+with+rheumatoid+arthritis.&amp;publication_year=2019&amp;journal=Arthritis+Rheumatol&amp;pages=1450-1459&amp;doi=10.1002%2Fart.40911&amp;pmid=31385441" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/4"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">4</span></span> • <span property="datePublished">January 27, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">316</span>-<span property="pageEnd">326</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: January 26, 2022</div><div><b class="core-label">Published in issue</b>: January 27, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/cardiology-general" alt="View article keyword Cardiology General" data-interactiontype="article_recirculation_click">Cardiology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/hematology-oncology-general" alt="View article keyword Hematology/Oncology General" data-interactiontype="article_recirculation_click">Hematology/Oncology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/rheumatoid-arthritis" alt="View article keyword Rheumatoid Arthritis" data-interactiontype="article_recirculation_click">Rheumatoid Arthritis</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Steven R.</span> <span property="familyName">Ytterberg</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Deepak L.</span> <span property="familyName">Bhatt</span>, <span property="honorificSuffix">M.D., M.P.H.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1278-6245" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1278-6245</a></span>, <span property="author" typeof="Person"><span property="givenName">Ted R.</span> <span property="familyName">Mikuls</span>, <span property="honorificSuffix">M.D., M.S.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gary G.</span> <span property="familyName">Koch</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Roy</span> <span property="familyName">Fleischmann</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jose L.</span> <span property="familyName">Rivas</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rebecca</span> <span property="familyName">Germino</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sujatha</span> <span property="familyName">Menon</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yanhui</span> <span property="familyName">Sun</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Cunshan</span> <span property="familyName">Wang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrea B.</span> <span property="familyName">Shapiro</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Keith S.</span> <span property="familyName">Kanik</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Carol A.</span> <span property="familyName">Connell</span>, <span property="honorificSuffix">R.N., Ph.D.</span></span>, for <span property="author" typeof="Person">the ORAL Surveillance Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Division of Rheumatology, Mayo Clinic, Rochester, MN (S.R.Y.); the Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston (D.L.B.); the Division of Rheumatology, University of Nebraska Medical Center, Omaha (T.R.M.); the Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill (G.G.K.); Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas (R.F.); Pfizer, Madrid (J.L.R.); Pfizer, New York (R.G.); Pfizer, Groton, CT (S.M., C.W., K.S.K., C.A.C.); Pfizer, Shanghai, China (Y.S.); and Pfizer, Peapack, NJ (A.B.S.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Ytterberg can be contacted at <a href="mailto:ytterberg.steven@mayo.edu">ytterberg.steven@mayo.edu</a> or at Mayo Clinic, 200 First St. SW, Rochester, MN 55905.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A list of the ORAL Surveillance investigators is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">1116</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2109927" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="136e4f09-4566-76c1-ca90-6c8f7af30d27"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603" style="display:inline-block;">
                <img alt="Article has an altmetric score of 623" src="https://badges.altmetric.com/?size=320&amp;score=623&amp;types=mabvctwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_136e4f09-4566-76c1-ca90-6c8f7af30d27" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=news">
          Picked up by <b>62</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=twitter">
          Posted by <b>191</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=patents">
          Referenced in <b>1</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=wikipedia">
          Referenced in <b>2</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=121620603&amp;tab=guidelines">
          Referenced in <b>8</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>688</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="9523b061f1b2f214-GRU"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2109927"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-4%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2109927%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="1116" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Seung-Hun You, </li><li class="list-inline-item cited-by__entry__author">Soo-Kyung Cho, </li><li class="list-inline-item cited-by__entry__author">Jeong-Yeon Kim, </li><li class="list-inline-item cited-by__entry__author">Yeo-Jin Song, </li><li class="list-inline-item cited-by__entry__author">Sun-Young Jung, </li><li class="list-inline-item cited-by__entry__author">Yoon-Kyoung Sung, </li></ul><span class="cited-by__entry__title">Risk of major adverse cardiovascular events following targeted therapy in patients with rheumatoid arthritis: a real-world analysis stratified by cardiovascular risk, </span><span class="cited-by__entry__series-title">Seminars in Arthritis and Rheumatism, </span><span class="cited-by__entry__volume"><strong>73</strong>, </span><span class="cited-by__entry__page-range">(152721), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semarthrit.2025.152721" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semarthrit.2025.152721</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semarthrit.2025.152721" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Soo-Kyung Cho, </li><li class="list-inline-item cited-by__entry__author">Se Rim Choi, </li><li class="list-inline-item cited-by__entry__author">Hye Won Kim, </li><li class="list-inline-item cited-by__entry__author">Eunwoo Nam, </li><li class="list-inline-item cited-by__entry__author">Sang Won Lee, </li><li class="list-inline-item cited-by__entry__author">Shin-Seok Lee, </li><li class="list-inline-item cited-by__entry__author">Hye-Soon Lee, </li><li class="list-inline-item cited-by__entry__author">Sung-Hoon Park, </li><li class="list-inline-item cited-by__entry__author">Yeon-Ah Lee, </li><li class="list-inline-item cited-by__entry__author">Sung Hae Chang, </li><li class="list-inline-item cited-by__entry__author">Min-Chan Park, </li><li class="list-inline-item cited-by__entry__author">Hyoun-Ah Kim, </li><li class="list-inline-item cited-by__entry__author">Seung-Ki Kwok, </li><li class="list-inline-item cited-by__entry__author">Hyun-Sook Kim, </li><li class="list-inline-item cited-by__entry__author">Bo Young Yoon, </li><li class="list-inline-item cited-by__entry__author">Yong-Gil Kim, </li><li class="list-inline-item cited-by__entry__author">Hae-Rim Kim, </li><li class="list-inline-item cited-by__entry__author">Jae Hoon Kim, </li><li class="list-inline-item cited-by__entry__author">Jisoo Lee, </li><li class="list-inline-item cited-by__entry__author">Jeongim Choi, </li><li class="list-inline-item cited-by__entry__author">Wan-Sik Uhm, </li><li class="list-inline-item cited-by__entry__author">Yoon-Kyoung Sung, </li></ul><span class="cited-by__entry__title">Real-world comparative effectiveness study of Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis, </span><span class="cited-by__entry__series-title">Seminars in Arthritis and Rheumatism, </span><span class="cited-by__entry__volume"><strong>73</strong>, </span><span class="cited-by__entry__page-range">(152720), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semarthrit.2025.152720" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semarthrit.2025.152720</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semarthrit.2025.152720" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Camille M. Powers, </li><li class="list-inline-item cited-by__entry__author">Madeline Kim, </li><li class="list-inline-item cited-by__entry__author">Annie Chang, </li><li class="list-inline-item cited-by__entry__author">Benjamin D. Hu, </li><li class="list-inline-item cited-by__entry__author">Brandon R. Block, </li><li class="list-inline-item cited-by__entry__author">Austin J. Piontkowski, </li><li class="list-inline-item cited-by__entry__author">Jeremy Orloff, </li><li class="list-inline-item cited-by__entry__author">Jade N. Young, </li><li class="list-inline-item cited-by__entry__author">Yeriel D. Estrada, </li><li class="list-inline-item cited-by__entry__author">Digpal S. Gour, </li><li class="list-inline-item cited-by__entry__author">Emma Guttman-Yassky, </li><li class="list-inline-item cited-by__entry__author">Nicholas Gulati, </li></ul><span class="cited-by__entry__title">Tape Strip Profiling of Checkpoint Inhibitor–Associated Dermatitis Highlights Pan-T-Cell Activation: A Pilot Study, </span><span class="cited-by__entry__series-title">JID Innovations, </span><span class="cited-by__entry__volume"><strong>5</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(100375), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.xjidi.2025.100375" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.xjidi.2025.100375</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.xjidi.2025.100375" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Wongelawit Zerihun, </li><li class="list-inline-item cited-by__entry__author">Joud Fahed, </li><li class="list-inline-item cited-by__entry__author">Danhue Moodie, </li><li class="list-inline-item cited-by__entry__author">Fana Cisse-Diouf, </li></ul><span class="cited-by__entry__title">Multivessel Coronary Artery Disease in a Patient Treated With Tofacitinib: A Case Report, </span><span class="cited-by__entry__series-title">Cureus, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7759/cureus.86235" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7759/cureus.86235</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7759/cureus.86235" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Soo Min Ahn, </li><li class="list-inline-item cited-by__entry__author">Seonok Kim, </li><li class="list-inline-item cited-by__entry__author">Ye-Jee Kim, </li><li class="list-inline-item cited-by__entry__author">Seokchan Hong, </li><li class="list-inline-item cited-by__entry__author">Chang-Keun Lee, </li><li class="list-inline-item cited-by__entry__author">Bin Yoo, </li><li class="list-inline-item cited-by__entry__author">Ji Seon Oh, </li><li class="list-inline-item cited-by__entry__author">Yong-Gil Kim, </li></ul><span class="cited-by__entry__title">Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study, </span><span class="cited-by__entry__series-title">PLOS One, </span><span class="cited-by__entry__volume"><strong>20</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(e0326311), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1371/journal.pone.0326311" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1371/journal.pone.0326311</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1371/journal.pone.0326311" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ilya Gurevic, </li><li class="list-inline-item cited-by__entry__author">Loic Meudec, </li><li class="list-inline-item cited-by__entry__author">Xavier Mariette, </li><li class="list-inline-item cited-by__entry__author">Gaetane Nocturne, </li><li class="list-inline-item cited-by__entry__author">Sara S. McCoy, </li></ul><span class="cited-by__entry__title">JAK inhibitor withdrawal causes a transient pro-inflammatory cascade: A potential mechanism for major adverse cardiac events, </span><span class="cited-by__entry__series-title">PLOS One, </span><span class="cited-by__entry__volume"><strong>20</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(e0311706), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1371/journal.pone.0311706" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1371/journal.pone.0311706</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1371/journal.pone.0311706" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Teodora Baciu, </li><li class="list-inline-item cited-by__entry__author">Adriana Elena Neagu, </li><li class="list-inline-item cited-by__entry__author">Ioana Cristina Saulescu, </li><li class="list-inline-item cited-by__entry__author">Daniela Opris-Belinski, </li></ul><span class="cited-by__entry__title">Unveiling Sex-Related Variability in Psoriatic Arthritis: A Call for Personalized Care, </span><span class="cited-by__entry__series-title">Journal of Clinical Medicine, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">12, </span><span class="cited-by__entry__page-range">(4124), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/jcm14124124" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/jcm14124124</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/jcm14124124" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nadia Eden, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Gaunt, </li><li class="list-inline-item cited-by__entry__author">Elaine Ming San Ong, </li><li class="list-inline-item cited-by__entry__author">Kassem Sharif, </li><li class="list-inline-item cited-by__entry__author">Christian Selinger, </li></ul><span class="cited-by__entry__title">The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease, </span><span class="cited-by__entry__series-title">British Journal of Hospital Medicine, </span><span class="cited-by__entry__page-range">(1-14), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.12968/hmed.2024.0798" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.12968/hmed.2024.0798</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.12968/hmed.2024.0798" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Gerd R Burmester, </li><li class="list-inline-item cited-by__entry__author">Eduardo Mysler, </li><li class="list-inline-item cited-by__entry__author">Peter Taylor, </li><li class="list-inline-item cited-by__entry__author">Stephen Hall, </li><li class="list-inline-item cited-by__entry__author">Bettina Wick-Urban, </li><li class="list-inline-item cited-by__entry__author">Andrew Garrison, </li><li class="list-inline-item cited-by__entry__author">Tianming Gao, </li><li class="list-inline-item cited-by__entry__author">Irina Fish, </li><li class="list-inline-item cited-by__entry__author">Sander Strengholt, </li><li class="list-inline-item cited-by__entry__author">Roy Fleischmann, </li></ul><span class="cited-by__entry__title">Benefit–risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease, </span><span class="cited-by__entry__series-title">RMD Open, </span><span class="cited-by__entry__volume"><strong>11</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(e005371), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1136/rmdopen-2024-005371" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1136/rmdopen-2024-005371</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1136/rmdopen-2024-005371" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Anneli Enblom Larsson, </li><li class="list-inline-item cited-by__entry__author">Henrik Renlund, </li><li class="list-inline-item cited-by__entry__author">Björn Andréasson, </li><li class="list-inline-item cited-by__entry__author">Henrik Holmberg, </li><li class="list-inline-item cited-by__entry__author">Maria Liljeholm, </li><li class="list-inline-item cited-by__entry__author">Anders Själander, </li></ul><span class="cited-by__entry__title">Thrombosis, major bleeding, and mortality in 1079 patients with myelofibrosis: a matched population-based study, </span><span class="cited-by__entry__series-title">Blood Advances, </span><span class="cited-by__entry__volume"><strong>9</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(2783-2793), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1182/bloodadvances.2025016247" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1182/bloodadvances.2025016247</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1182/bloodadvances.2025016247" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-4%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2109927%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2109927" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2109927" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2109927.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f1.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/95d72be3-9229-47bb-aef1-86930d215152/assets/images/large/nejmoa2109927_f1.jpg" height="1958" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Hazard Ratios and Incidence Rates for Adjudicated MACE (Safety Analysis Population, 60-Day On-Treatment Time).</div><div class="notes"><div role="doc-footnote">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. The number needed to harm (NNH) was the number of patient-years of exposure to tofacitinib required to have one additional major adverse cardiovascular event (MACE), relative to a tumor necrosis factor (TNF) inhibitor; calculations were performed post hoc. The NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than with a TNF inhibitor to result in one additional MACE; calculations were performed post hoc. P values for the testing of the null hypotheses of no difference between treatments were for hypothesis generation and descriptive purposes only (post hoc). The P values were 0.14 for the combined tofacitinib doses as compared with a TNF inhibitor, 0.48 for tofacitinib at a dose of 10 mg twice daily as compared with tofacitinib at a dose of 5 mg twice daily, 0.33 for tofacitinib at a dose of 5 mg twice daily as compared with a TNF inhibitor, and 0.10 for tofacitinib at a dose of 10 mg twice daily as compared with a TNF inhibitor. The 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f2.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/8ee92f74-9d41-4241-94d0-c77182f5a005/assets/images/large/nejmoa2109927_f2.jpg" height="1958" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Hazard Ratios and Incidence Rates for Adjudicated Cancers, Excluding NMSC (Safety Analysis Population, Total-Time Analysis).</div><div class="notes"><div role="doc-footnote">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. The NNH was the number of patient-years of exposure to tofacitinib required to have one additional cancer, relative to a TNF inhibitor; calculations were performed post hoc. The NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than with a TNF inhibitor to result in one additional cancer; calculations were performed post hoc. P values for the testing of the null hypotheses of no difference between treatments were for hypothesis generation and descriptive purposes only (post hoc). The P values were 0.03 for the combined tofacitinib doses as compared with a TNF inhibitor, 0.99 for tofacitinib at a dose of 10 mg twice daily as compared with tofacitinib at a dose of 5 mg twice daily, 0.05 for tofacitinib at a dose of 5 mg twice daily as compared with a TNF inhibitor, and 0.05 for tofacitinib at a dose of 10 mg twice daily as compared with a TNF inhibitor. The 𝙸 bars represent 95% confidence intervals. NMSC denotes nonmelanoma skin cancer.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f3.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/8fcc68a3-8f70-4f6d-8d13-e7cc80a5f37b/assets/images/large/nejmoa2109927_f3.jpg" height="1698" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Least-Squares Mean Change from Baseline in SDAI Score (Full Analysis Population, On-Treatment Time).</div><div class="notes"><div role="doc-footnote">Simplified Disease Activity Index (SDAI) scores range from 0 to 100, with higher scores indicating more disease activity.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18 r19" id="core-body-ref-r19-2" href-manipulated="true" data-to-manipulate="false">17-19</a></sup> For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. Data were derived from a mixed model for repeated measures, with fixed effects for trial group, visit, interaction between trial group and visit, baseline value, and interaction between baseline value and visit, without imputation for missing values. A common heterogeneous compound symmetry covariance matrix was used. The 95% confidence intervals (indicated by 𝙸 bars) for all efficacy data were not adjusted for multiplicity and therefore should not be used to infer treatment effects. On-treatment time includes data on or before the trial treatment end date. Only visits with more than 50 patients for each treatment group were included.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2109927/asset/47d6baaa-a021-4214-8baf-5bbcb7ce3fef/assets/images/large/nejmoa2109927_t1.jpg" height="1804" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Tofacitinib, 5 mg Twice Daily<br>(N=1455)</th><th class="txxx-borders">Tofacitinib, 10 mg Twice Daily<br>(N=1456)<a href="#core-t1fn2" role="doc-noteref">†</a></th><th class="txxx-borders">TNF Inhibitor<br>(N=1451)</th><th class="txxr-borders">Total<br>(N=4362)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">60.8±6.8</td><td class="xxxx-borders">61.4±7.1</td><td class="xxxx-borders">61.3±7.5</td><td class="xxxr-borders">61.2±7.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">≥65 yr — no. (%)</td><td class="xxxx-borders shading">413 (28.4)</td><td class="xxxx-borders shading">478 (32.8)</td><td class="xxxx-borders shading">462 (31.8)</td><td class="xxxr-borders shading">1353 (31.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">1169 (80.3)</td><td class="xxxx-borders">1124 (77.2)</td><td class="xxxx-borders">1117 (77.0)</td><td class="xxxr-borders">3410 (78.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">1128 (77.5)</td><td class="xxxx-borders">1126 (77.3)</td><td class="xxxx-borders">1099 (75.7)</td><td class="xxxr-borders">3353 (76.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">63 (4.3)</td><td class="xxxx-borders shading">65 (4.5)</td><td class="xxxx-borders shading">83 (5.7)</td><td class="xxxr-borders shading">211 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Asian</td><td class="xxxx-borders">65 (4.5)</td><td class="xxxx-borders">56 (3.8)</td><td class="xxxx-borders">55 (3.8)</td><td class="xxxr-borders">176 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">199 (13.7)</td><td class="xxxx-borders shading">209 (14.4)</td><td class="xxxx-borders shading">214 (14.7)</td><td class="xxxr-borders shading">622 (14.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Smoking status — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Never smoked</td><td class="xxxx-borders shading">735 (50.5)</td><td class="xxxx-borders shading">752 (51.6)</td><td class="xxxx-borders shading">772 (53.2)</td><td class="xxxr-borders shading">2259 (51.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Ever smoked</td><td class="xxxx-borders">720 (49.5)</td><td class="xxxx-borders">704 (48.4)</td><td class="xxxx-borders">679 (46.8)</td><td class="xxxr-borders">2103 (48.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">History of hypertension — no. (%)</td><td class="xxxx-borders shading">955 (65.6)</td><td class="xxxx-borders shading">954 (65.5)</td><td class="xxxx-borders shading">969 (66.8)</td><td class="xxxr-borders shading">2878 (66.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">History of diabetes mellitus — no. (%)</td><td class="xxxx-borders">243 (16.7)</td><td class="xxxx-borders">261 (17.9)</td><td class="xxxx-borders">255 (17.6)</td><td class="xxxr-borders">759 (17.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">History of venous thromboembolism — no. (%)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">19 (1.3)</td><td class="xxxx-borders shading">33 (2.3)</td><td class="xxxx-borders shading">27 (1.9)</td><td class="xxxr-borders shading">79 (1.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">History of extraarticular disease — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">532 (36.6)</td><td class="xxxx-borders">521 (35.8)</td><td class="xxxx-borders">552 (38.0)</td><td class="xxxr-borders">1605 (36.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">History of coronary heart disease — no. (%)</td><td class="xxxx-borders shading">161 (11.1)</td><td class="xxxx-borders shading">172 (11.8)</td><td class="xxxx-borders shading">164 (11.3)</td><td class="xxxr-borders shading">497 (11.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Family history of coronary heart disease — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">First-degree male relative &lt;55 yr of age</td><td class="xxxx-borders shading">154 (10.6)</td><td class="xxxx-borders shading">132 (9.1)</td><td class="xxxx-borders shading">151 (10.4)</td><td class="xxxr-borders shading">437 (10.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">First-degree female relative &lt;65 yr of age</td><td class="xxxx-borders">115 (7.9)</td><td class="xxxx-borders">107 (7.3)</td><td class="xxxx-borders">100 (6.9)</td><td class="xxxr-borders">322 (7.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Fasting HDL cholesterol &lt;40 mg/dl — no. (%)</td><td class="xbxx-borders shading">172 (11.8)</td><td class="xbxx-borders shading">195 (13.4)</td><td class="xbxx-borders shading">173 (11.9)</td><td class="xbxr-borders shading">540 (12.4)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. HDL denotes high-density lipoprotein, and TNF tumor necrosis factor.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily or who discontinued the trial drug were counted in the group receiving 10 mg twice daily.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Race was reported by the patient.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Venous thromboembolism included deep-vein thrombosis and pulmonary embolism.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Extraarticular disease included nodules, Sjögren’s syndrome, anemia of chronic disease, pulmonary manifestations, or other clinical features as identified by the site investigator.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Safety Analysis Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2109927/asset/03b51f31-5f31-4c4b-81b1-d318b1a475d5/assets/images/large/nejmoa2109927_t2.jpg" height="2015" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Tofacitinib, 5 mg Twice Daily<br>(N=1455)</th><th class="txxx-borders">Tofacitinib, 10 mg Twice Daily<br>(N=1456)<a href="#core-t2fn2" role="doc-noteref">†</a></th><th class="txxr-borders">TNF Inhibitor<br>(N=1451)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event — no. (%)</td><td class="xxxx-borders shading">1333 (91.6)</td><td class="xxxx-borders shading">1344 (92.3)</td><td class="xxxr-borders shading">1308 (90.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders">351 (24.1)</td><td class="xxxx-borders">390 (26.8)</td><td class="xxxr-borders">306 (21.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Discontinuation of trial treatment due to adverse event — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Permanent discontinuation<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">210 (14.4)</td><td class="xxxx-borders">304 (20.9)</td><td class="xxxr-borders">210 (14.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Temporary discontinuation<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">665 (45.7)</td><td class="xxxx-borders shading">736 (50.5)</td><td class="xxxr-borders shading">576 (39.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Adverse events of special interest</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious infection — no. (%)</td><td class="xxxx-borders shading">141 (9.7)</td><td class="xxxx-borders shading">169 (11.6)</td><td class="xxxr-borders shading">119 (8.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.17 (0.92–1.50)</td><td class="xxxx-borders">1.48 (1.17–1.87)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated opportunistic infection — no. (%)<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">39 (2.7)</td><td class="xxxx-borders shading">44 (3.0)</td><td class="xxxr-borders shading">21 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.82 (1.07–3.09)</td><td class="xxxx-borders">2.17 (1.29–3.66)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">All herpes zoster, serious and nonserious — no. (%)<a href="#core-t2fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">180 (12.4)</td><td class="xxxx-borders shading">178 (12.2)</td><td class="xxxr-borders shading">58 (4.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">3.28 (2.44–4.41)</td><td class="xxxx-borders">3.39 (2.52–4.55)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated hepatic event — no. (%)</td><td class="xxxx-borders shading">46 (3.2)</td><td class="xxxx-borders shading">72 (4.9)</td><td class="xxxr-borders shading">35 (2.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.29 (0.83–2.00)</td><td class="xxxx-borders">2.14 (1.43–3.21)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated NMSC — no. (%)</td><td class="xxxx-borders shading">31 (2.1)</td><td class="xxxx-borders shading">33 (2.3)</td><td class="xxxr-borders shading">16 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.90 (1.04–3.47)</td><td class="xxxx-borders">2.16 (1.19–3.92)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated pulmonary embolism — no. (%)</td><td class="xxxx-borders shading">9 (0.6)</td><td class="xxxx-borders shading">24 (1.6)</td><td class="xxxr-borders shading">3 (0.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">2.93 (0.79–10.83)</td><td class="xxxx-borders">8.26 (2.49–27.43)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated DVT — no. (%)</td><td class="xxxx-borders shading">11 (0.8)</td><td class="xxxx-borders shading">15 (1.0)</td><td class="xxxr-borders shading">7 (0.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.54 (0.60–3.97)</td><td class="xxxx-borders">2.21 (0.90–5.43)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated VTE — no. (%)</td><td class="xxxx-borders shading">17 (1.2)</td><td class="xxxx-borders shading">34 (2.3)</td><td class="xxxr-borders shading">10 (0.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xxxx-borders">1.66 (0.76–3.63)</td><td class="xxxx-borders">3.52 (1.74–7.12)</td><td class="xxxr-borders">Referent</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Adjudicated death from any cause — no. (%)</td><td class="xxxx-borders shading">26 (1.8)</td><td class="xxxx-borders shading">39 (2.7)</td><td class="xxxr-borders shading">17 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Hazard ratio vs. TNF inhibitor (95% CI)</td><td class="xbxx-borders">1.49 (0.81–2.74)</td><td class="xbxx-borders">2.37 (1.34–4.18)</td><td class="xbxr-borders">Referent</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Shown are adverse events that emerged or worsened during the 28-day on-treatment period, which was defined as the minimum of the date of last contact or the date of the last dose of a trial treatment plus 28 days. DVT denotes deep-vein thrombosis, NMSC nonmelanoma skin cancer, and VTE venous thromboembolism.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Data are based on the adverse-event and disposition case-report forms.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">At the discretion of the investigator, discontinuations of trial medication were allowed, not to exceed 2 months, for safety issues.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Also included are opportunistic herpes zoster and tuberculosis events.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">Included are herpes zoster adjudicated as an opportunistic infection and nonadjudicated herpes zoster events.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events (Safety Analysis Population, 28-Day On-Treatment Time).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2109927_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2109927</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. <em>Lancet</em> 2010;376:1094-1108.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(10)60826-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20870100/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282411600037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rheumatoid+arthritis.&amp;publication_year=2010&amp;journal=Lancet&amp;pages=1094-1108&amp;doi=10.1016%2FS0140-6736%2810%2960826-4&amp;pmid=20870100" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <em>Arthritis Rheumatol</em> 2021;73:1108-1123.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.41752" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34101376/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2021+American+College+of+Rheumatology+guideline+for+the+treatment+of+rheumatoid+arthritis.&amp;publication_year=2021&amp;journal=Arthritis+Rheumatol&amp;pages=1108-1123&amp;doi=10.1002%2Fart.41752&amp;pmid=34101376" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <em>Ann Rheum Dis</em> 2020;79:685-699.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2019-216655" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31969328/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000557252600024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=EULAR+recommendations+for+the+management+of+rheumatoid+arthritis+with+synthetic+and+biological+disease-modifying+antirheumatic+drugs%3A+2019+update.&amp;publication_year=2020&amp;journal=Ann+Rheum+Dis&amp;pages=685-699&amp;doi=10.1136%2Fannrheumdis-2019-216655&amp;pmid=31969328" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. <em>Lancet</em> 2015;386:258-265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(14)61704-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25975452/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000358213700030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+serious+infection+in+biological+treatment+of+patients+with+rheumatoid+arthritis%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2015&amp;journal=Lancet&amp;pages=258-265&amp;doi=10.1016%2FS0140-6736%2814%2961704-9&amp;pmid=25975452" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <em>Rheumatology (Oxford)</em> 2019;58:1755-1766.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/kez087" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30982883/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491255500010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+systematic+review+and+meta-analysis+of+infection+risk+with+small+molecule+JAK+inhibitors+in+rheumatoid+arthritis.&amp;publication_year=2019&amp;journal=Rheumatology+%28Oxford%29&amp;pages=1755-1766&amp;doi=10.1093%2Frheumatology%2Fkez087&amp;pmid=30982883" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. <em>Arthritis Rheum</em> 1996;39:723-731.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.1780390503" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8639168/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Guidelines+for+monitoring+drug+therapy+in+rheumatoid+arthritis.&amp;publication_year=1996&amp;journal=Arthritis+Rheum&amp;pages=723-731&amp;doi=10.1002%2Fart.1780390503&amp;pmid=8639168" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. <em>Ann Intern Med</em> 2020;172:369-380.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M19-3369" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32066146/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000520170800023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Adverse+effects+of+low-dose+methotrexate%3A+a+randomized+trial.&amp;publication_year=2020&amp;journal=Ann+Intern+Med&amp;pages=369-380&amp;doi=10.7326%2FM19-3369&amp;pmid=32066146" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. <em>Semin Arthritis Rheum</em> 2020;50:930-937.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.semarthrit.2020.08.007" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32906027/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000580602000022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+malignancy+with+non-TNFi+biologic+or+tofacitinib+therapy+in+rheumatoid+arthritis%3A+a+meta-analysis+of+observational+studies.&amp;publication_year=2020&amp;journal=Semin+Arthritis+Rheum&amp;pages=930-937&amp;doi=10.1016%2Fj.semarthrit.2020.08.007&amp;pmid=32906027" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Kremer JM, Bingham CO III, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. <em>ACR Open Rheumatol</em> 2021;3:173-184.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr2.11232" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33570260/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Postapproval+comparative+safety+study+of+tofacitinib+and+biological+disease-modifying+antirheumatic+drugs%3A+5-year+results+from+a+United+States-based+rheumatoid+arthritis+registry.&amp;publication_year=2021&amp;journal=ACR+Open+Rheumatol&amp;pages=173-184&amp;doi=10.1002%2Facr2.11232&amp;pmid=33570260" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. <em>Joint Bone Spine</em> 2017;84:133-140.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jbspin.2016.02.028" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27341745/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000396444100004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+of+biologic+DMARDs+in+RA+patients+in+real+life%3A+a+systematic+literature+review+and+meta-analyses+of+biologic+registers.&amp;publication_year=2017&amp;journal=Joint+Bone+Spine&amp;pages=133-140&amp;doi=10.1016%2Fj.jbspin.2016.02.028&amp;pmid=27341745" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Singh S, Fumery M, Singh AG, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. <em>Arthritis Care Res (Hoboken)</em> 2020;72:561-576.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.23875" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30875456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521664600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+risk+of+cardiovascular+events+with+biologic+and+synthetic+disease-modifying+antirheumatic+drugs+in+patients+with+rheumatoid+arthritis%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2020&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=561-576&amp;doi=10.1002%2Facr.23875&amp;pmid=30875456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). <em>J Immunol</em> 2011;186:4234-4243.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4049/jimmunol.1003668" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21383241/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000288751200048" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Modulation+of+innate+and+adaptive+immune+responses+by+tofacitinib+%28CP-690%2C550%29.&amp;publication_year=2011&amp;journal=J+Immunol&amp;pages=4234-4243&amp;doi=10.4049%2Fjimmunol.1003668&amp;pmid=21383241" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. <em>J Inflamm (Lond)</em> 2010;7:41-41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1476-9255-7-41" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20701804/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282350100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis.&amp;publication_year=2010&amp;journal=J+Inflamm+%28Lond%29&amp;pages=41-41&amp;doi=10.1186%2F1476-9255-7-41&amp;pmid=20701804" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. <em>Arthritis Rheumatol</em> 2015;67:616-625.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.38974" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25470338/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Potential+mechanisms+leading+to+the+abnormal+lipid+profile+in+patients+with+rheumatoid+arthritis+versus+healthy+volunteers+and+reversal+by+tofacitinib.&amp;publication_year=2015&amp;journal=Arthritis+Rheumatol&amp;pages=616-625&amp;doi=10.1002%2Fart.38974&amp;pmid=25470338" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] cancers, including lymphoma, were observed, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r14-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by reduced cholesterol ester catabolism </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Charles-Schoeman C, Gonzalez-Gay MA, Kaplan I, et al. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. <em>Semin Arthritis Rheum</em> 2016;46:71-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.semarthrit.2016.03.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27079757/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000381447200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effects+of+tofacitinib+and+other+DMARDs+on+lipid+profiles+in+rheumatoid+arthritis%3A+implications+for+the+rheumatologist.&amp;publication_year=2016&amp;journal=Semin+Arthritis+Rheum&amp;pages=71-80&amp;doi=10.1016%2Fj.semarthrit.2016.03.004&amp;pmid=27079757" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content"><em>Xeljanz (tofacitinib): highlights of prescribing information</em>. New York: Pfizer, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Xeljanz+%28tofacitinib%29%3A+highlights+of+prescribing+information&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. <em>Rheumatology (Oxford)</em> 2003;42:244-257.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/rheumatology/keg072" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/12595618/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000181378100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+simplified+disease+activity+index+for+rheumatoid+arthritis+for+use+in+clinical+practice.&amp;publication_year=2003&amp;journal=Rheumatology+%28Oxford%29&amp;pages=244-257&amp;doi=10.1093%2Frheumatology%2Fkeg072&amp;pmid=12595618" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Disease Activity Index (SDAI) score </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r17-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Anderson JK, Zimmerman L, Caplan L, Michaud K. Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score with ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). <em>Arthritis Care Res (Hoboken)</em> 2011;63:Suppl 11:S14-S36.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20621" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22588741/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297219500003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measures+of+rheumatoid+arthritis+disease+activity%3A+Patient+%28PtGA%29+and+Provider+%28PrGA%29+Global+Assessment+of+Disease+Activity%2C+Disease+Activity+Score+%28DAS%29+and+Disease+Activity+Score+with+28-Joint+Counts+%28DAS28%29%2C+Simplified+Disease+Activity+Index+%28SDAI%29%2C+Clinical+Disease+Activity+Index+%28CDAI%29%2C+Patient+Activity+Score+%28PAS%29+and+Patient+Activity+Score-II+%28PASII%29%2C+Routine+Assessment+of+Patient+Index+Data+%28RAPID%29%2C+Rheumatoid+Arthritis+Disease+Activity+Index+%28RADAI%29+and+Rheumatoid+Arthritis+Disease+Activity+Index-5+%28RADAI-5%29%2C+Chronic+Arthritis+Systemic+Index+%28CASI%29%2C+Patient-Based+Disease+Activity+Score+with+ESR+%28PDAS1%29+and+Patient-Based+Disease+Activity+Score+without+ESR+%28PDAS2%29%2C+and+Mean+Overall+Index+for+Rheumatoid+Arthritis+%28MOI-RA%29.&amp;publication_year=2011&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=S14-S36&amp;doi=10.1002%2Facr.20621&amp;pmid=22588741" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Disease Activity Index (SDAI) score </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r18-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Smolen JS, Aletaha D. Scores for all seasons: SDAI and CDAI. <em>Clin Exp Rheumatol</em> 2014;32:Suppl 85:S-75–S-79.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25365093/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000344721300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Scores+for+all+seasons%3A+SDAI+and+CDAI.&amp;publication_year=2014&amp;journal=Clin+Exp+Rheumatol&amp;pages=S-75-S-79&amp;pmid=25365093" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Disease Activity Index (SDAI) score </span></a></li><li role="none"><a class="to-citation open-in-viewer" href="#f3" role="menuitem" data-target="#fv-body-ref-r19-2"><i aria-hidden="true" class="icon-return"></i><span>b [...] scores indicating more disease activity. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Maska L, Anderson J, Michaud K. Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality of Life (RAQoL). <em>Arthritis Care Res (Hoboken)</em> 2011;63:Suppl 11:S4-S13.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20620" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22588760/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000297219500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measures+of+functional+status+and+quality+of+life+in+rheumatoid+arthritis%3A+Health+Assessment+Questionnaire+Disability+Index+%28HAQ%29%2C+Modified+Health+Assessment+Questionnaire+%28MHAQ%29%2C+Multidimensional+Health+Assessment+Questionnaire+%28MDHAQ%29%2C+Health+Assessment+Questionnaire+II+%28HAQ-II%29%2C+Improved+Health+Assessment+Questionnaire+%28Improved+HAQ%29%2C+and+Rheumatoid+Arthritis+Quality+of+Life+%28RAQoL%29.&amp;publication_year=2011&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=S4-S13&amp;doi=10.1002%2Facr.20620&amp;pmid=22588760" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. <em>Arthritis Rheum</em> 2005;52:2625-2636.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r21-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.21235" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16142705/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Remission+and+active+disease+in+rheumatoid+arthritis%3A+defining+criteria+for+disease+activity+states.&amp;publication_year=2005&amp;journal=Arthritis+Rheum&amp;pages=2625-2636&amp;doi=10.1002%2Fart.21235&amp;pmid=16142705" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r21-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r21-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] low disease activity (score of ≤11) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r21-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and remission (score of ≤3.3), </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Guidance for industry. 2008 (<a href="https://www.fda.gov/media/71297/download">https://www.fda.gov/media/71297/download</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Diabetes+mellitus+%E2%80%94+evaluating+cardiovascular+risk+in+new+antidiabetic+therapies+to+treat+type+2+diabetes.+Guidance+for+industry&amp;publication_year=2008" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. <em>Comput Biol Med</em> 1992;22:351-361.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0010-4825(92)90023-G" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/1424580/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1992JU25200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Simple+SAS+macros+for+the+calculation+of+exact+binomial+and+Poisson+confidence+limits.&amp;publication_year=1992&amp;journal=Comput+Biol+Med&amp;pages=351-361&amp;doi=10.1016%2F0010-4825%2892%2990023-G&amp;pmid=1424580" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy — report of the ISPOR risk-benefit management working group. <em>Value Health</em> 2010;13:657-666.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1524-4733.2010.00725.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20412543/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280674200020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+review+of+quantitative+risk-benefit+methodologies+for+assessing+drug+safety+and+efficacy+%E2%80%94+report+of+the+ISPOR+risk-benefit+management+working+group.&amp;publication_year=2010&amp;journal=Value+Health&amp;pages=657-666&amp;doi=10.1111%2Fj.1524-4733.2010.00725.x&amp;pmid=20412543" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Strait A, Castillo F, Choden S, et al. Demographic characteristics of participants in rheumatoid arthritis randomized clinical trials: a systematic review. <em>JAMA Netw Open</em> 2019;2(11):e1914745-e1914745.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamanetworkopen.2019.14745" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31722023/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505224400030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Demographic+characteristics+of+participants+in+rheumatoid+arthritis+randomized+clinical+trials%3A+a+systematic+review.&amp;publication_year=2019&amp;journal=JAMA+Netw+Open&amp;pages=e1914745-e1914745&amp;doi=10.1001%2Fjamanetworkopen.2019.14745&amp;pmid=31722023" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Aviña-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. <em>Ann Rheum Dis</em> 2012;71:1524-1529.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/annrheumdis-2011-200726" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22425941/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000307646500016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+incident+cardiovascular+events+in+patients+with+rheumatoid+arthritis%3A+a+meta-analysis+of+observational+studies.&amp;publication_year=2012&amp;journal=Ann+Rheum+Dis&amp;pages=1524-1529&amp;doi=10.1136%2Fannrheumdis-2011-200726&amp;pmid=22425941" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. <em>Arthritis Res Ther</em> 2015;17:212-212.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13075-015-0728-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26271620/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000359526300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+malignancy+in+adult+patients+with+rheumatoid+arthritis%3A+a+meta-analysis.&amp;publication_year=2015&amp;journal=Arthritis+Res+Ther&amp;pages=212-212&amp;doi=10.1186%2Fs13075-015-0728-9&amp;pmid=26271620" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. <em>Ann Rheum Dis</em> 2011;70:8-14.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/ard.2010.142133" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21109513/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285381100003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cardiovascular+disease+in+rheumatoid+arthritis%3A+state+of+the+art+and+future+perspectives.&amp;publication_year=2011&amp;journal=Ann+Rheum+Dis&amp;pages=8-14&amp;doi=10.1136%2Fard.2010.142133&amp;pmid=21109513" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Szekanecz Z, Szekanecz E, Bakó G, Shoenfeld Y. Malignancies in autoimmune rheumatic diseases — a mini-review. <em>Gerontology</em> 2011;57:3-10.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000314634" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20453490/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285580900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Malignancies+in+autoimmune+rheumatic+diseases+%E2%80%94+a+mini-review.&amp;publication_year=2011&amp;journal=Gerontology&amp;pages=3-10&amp;doi=10.1159%2F000314634&amp;pmid=20453490" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. <em>N Engl J Med</em> 2017;377:1119-1131.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_31_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2109927&amp;key=10.1056%2FNEJMoa1707914&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28845751/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000411348500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Antiinflammatory+therapy+with+canakinumab+for+atherosclerotic+disease.&amp;publication_year=2017&amp;journal=N+Engl+J+Med&amp;pages=1119-1131&amp;doi=10.1056%2FNEJMoa1707914&amp;pmid=28845751" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Barnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. <em>Arthritis Care Res (Hoboken)</em> 2011;63:522-529.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/acr.20371" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20957658/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000289422700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+review+and+meta-analysis%3A+anti-tumor+necrosis+factor+%CE%B1+therapy+and+cardiovascular+events+in+rheumatoid+arthritis.&amp;publication_year=2011&amp;journal=Arthritis+Care+Res+%28Hoboken%29&amp;pages=522-529&amp;doi=10.1002%2Facr.20371&amp;pmid=20957658" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. <em>Arthritis Rheumatol</em> 2019;71:1450-1459.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/art.40911" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31385441/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+factors+for+major+adverse+cardiovascular+events+in+phase+III+and+long-term+extension+studies+of+tofacitinib+in+patients+with+rheumatoid+arthritis.&amp;publication_year=2019&amp;journal=Arthritis+Rheumatol&amp;pages=1450-1459&amp;doi=10.1002%2Fart.40911&amp;pmid=31385441" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">May 04, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2202778" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 26, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2117663" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis — Past, Present, and Future</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.A. Singh</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 19, 2025</div><div class="nejm-widget_item"><div><span> Lawrence, Massachusetts</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891226/primary-care-physician-lawrence-ma/?query=fjwp&amp;rid=428606">Primary Care Physician, Lawrence, MA</a></div></div><div class="nejm-widget_item"><div><span> Brockton, Massachusetts</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/895942/ob-gyn-hospitalist-physician-for-signature-healthcare-brockton-ma/?query=fjwp&amp;rid=11031">OB/GYN Hospitalist Physician for Signature Healthcare - Brockton, MA</a></div></div><div class="nejm-widget_item"><div><span> Portland, Oregon</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/896007/epileptologist/?query=fjwf&amp;rid=329661">Epileptologist</a></div></div><div class="nejm-widget_item"><div><span> Cambridge, Massachusetts</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891377/team-leader-first-episode-psychosis-program-recovery-in-shared-experiences-rise-/?query=fjwp&amp;rid=1038">Team Leader, First-Episode Psychosis Program: Recovery In Shared Experiences (RISE)</a></div></div><div class="nejm-widget_item"><div><span> Cleveland, Ohio</span></div><div><span>Geriatrics</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889356/geriatrician/?query=fjwf&amp;rid=2201">Geriatrician</a></div></div><div class="nejm-widget_item"><div><span> Rochester, New York</span></div><div><span>Pathology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880756/surgical-pathology-physician/?query=fjwf&amp;rid=74241">Surgical Pathology Physician</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2109927&amp;pubId=41395836&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="9523b061f1b2f214-GRU">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="9523b061f1b2f214-GRU"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="9523b061f1b2f214-GRU"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$689382994$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$689382994$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$689382994$--></div></div><div class="mlt-body"><!--?lit$689382994$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$689382994$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$689382994$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$689382994$-->Jul 27, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2307020?query=recirc_Semantic" target="_self">Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis</a></div><div class="mlt-article-authors"><!--?lit$689382994$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$689382994$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$689382994$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$689382994$-->Jun 29, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2207940?query=recirc_Semantic" target="_self">Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis</a></div><div class="mlt-article-authors"><!--?lit$689382994$-->G. D’Haens and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$689382994$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$689382994$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$689382994$-->Jul 29, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2101643?query=recirc_Semantic" target="_self">Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia</a></div><div class="mlt-article-authors"><!--?lit$689382994$-->P.O. Guimarães and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$689382994$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$689382994$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$689382994$-->Jun 11, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2002527?query=recirc_Semantic" target="_self">Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy</a></div><div class="mlt-article-authors"><!--?lit$689382994$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$689382994$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$689382994$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$689382994$-->May 29, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2503584?query=recirc_Semantic" target="_self">Upadacitinib — An Up-and-Comer for Treatment of Giant-Cell Arteritis</a></div><div class="mlt-article-authors"><!--?lit$689382994$-->M.J. Koster and K.J. Warrington</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2109927?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2109927" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2109927.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2109927"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2116846" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2115961" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f1.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/95d72be3-9229-47bb-aef1-86930d215152/assets/images/large/nejmoa2109927_f1.jpg" height="1958" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Hazard Ratios and Incidence Rates for Adjudicated MACE (Safety Analysis Population, 60-Day On-Treatment Time).</div><div class="notes"><div role="doc-footnote">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. The number needed to harm (NNH) was the number of patient-years of exposure to tofacitinib required to have one additional major adverse cardiovascular event (MACE), relative to a tumor necrosis factor (TNF) inhibitor; calculations were performed post hoc. The NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than with a TNF inhibitor to result in one additional MACE; calculations were performed post hoc. P values for the testing of the null hypotheses of no difference between treatments were for hypothesis generation and descriptive purposes only (post hoc). The P values were 0.14 for the combined tofacitinib doses as compared with a TNF inhibitor, 0.48 for tofacitinib at a dose of 10 mg twice daily as compared with tofacitinib at a dose of 5 mg twice daily, 0.33 for tofacitinib at a dose of 5 mg twice daily as compared with a TNF inhibitor, and 0.10 for tofacitinib at a dose of 10 mg twice daily as compared with a TNF inhibitor. The 𝙸 bars represent 95% confidence intervals.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f2.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/8ee92f74-9d41-4241-94d0-c77182f5a005/assets/images/large/nejmoa2109927_f2.jpg" height="1958" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Hazard Ratios and Incidence Rates for Adjudicated Cancers, Excluding NMSC (Safety Analysis Population, Total-Time Analysis).</div><div class="notes"><div role="doc-footnote">For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. The NNH was the number of patient-years of exposure to tofacitinib required to have one additional cancer, relative to a TNF inhibitor; calculations were performed post hoc. The NNH over a period of 5 years was the number of patients who would need to be treated for that duration with tofacitinib rather than with a TNF inhibitor to result in one additional cancer; calculations were performed post hoc. P values for the testing of the null hypotheses of no difference between treatments were for hypothesis generation and descriptive purposes only (post hoc). The P values were 0.03 for the combined tofacitinib doses as compared with a TNF inhibitor, 0.99 for tofacitinib at a dose of 10 mg twice daily as compared with tofacitinib at a dose of 5 mg twice daily, 0.05 for tofacitinib at a dose of 5 mg twice daily as compared with a TNF inhibitor, and 0.05 for tofacitinib at a dose of 10 mg twice daily as compared with a TNF inhibitor. The 𝙸 bars represent 95% confidence intervals. NMSC denotes nonmelanoma skin cancer.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2109927_f3.jpg"><img src="/cms/10.1056/NEJMoa2109927/asset/8fcc68a3-8f70-4f6d-8d13-e7cc80a5f37b/assets/images/large/nejmoa2109927_f3.jpg" height="1698" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Least-Squares Mean Change from Baseline in SDAI Score (Full Analysis Population, On-Treatment Time).</div><div class="notes"><div role="doc-footnote">Simplified Disease Activity Index (SDAI) scores range from 0 to 100, with higher scores indicating more disease activity.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18 r19" id="fv-body-ref-r19-2" href-manipulated="true" data-to-manipulate="false">17-19</a></sup> For patients assigned to receive tofacitinib at a dose of 10 mg twice daily who had their dose reduced to 5 mg twice daily, the data collected after patients had been switched to 5 mg twice daily were counted in the group receiving 10 mg twice daily. Data were derived from a mixed model for repeated measures, with fixed effects for trial group, visit, interaction between trial group and visit, baseline value, and interaction between baseline value and visit, without imputation for missing values. A common heterogeneous compound symmetry covariance matrix was used. The 95% confidence intervals (indicated by 𝙸 bars) for all efficacy data were not adjusted for multiplicity and therefore should not be used to infer treatment effects. On-treatment time includes data on or before the trial treatment end date. Only visits with more than 50 patients for each treatment group were included.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Safety Analysis Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events (Safety Analysis Population, 28-Day On-Treatment Time).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/4" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 4</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 27, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2115304" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H. Tilly and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 27, 2022</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2116846" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.L. Gottlieb and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 27, 2022</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2115481" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">N. Andrews and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2109927%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2109927&amp;pubId=41395836&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2109927%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2109927&amp;pubId=41395836&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id05950251108946948" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="9523b061f1b2f214-GRU" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="9523b061f1b2f214-GRU" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="9523b061f1b2f214-GRU"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="9523b061f1b2f214-GRU"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="9523b061f1b2f214-GRU"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="9523b061f1b2f214-GRU">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="9523b061f1b2f214-GRU">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="9523b061f1b2f214-GRU"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="9523b061f1b2f214-GRU"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9523b061de8bf214',t:'MTc1MDM0MzA1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;9523b061de8bf214&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.6.2&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2109927?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=11-19"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-transactionid="2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" id="captureIFrame_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" target="captureIFrame_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="capture_screen"><input id="capture_signIn_js_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="js_version"><input id="capture_signIn_transactionId_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" type="hidden" class="capture_transactionId_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="capture_transactionId"><input id="capture_signIn_form_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="form"><input id="capture_signIn_flow_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="flow"><input id="capture_signIn_client_id_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="client_id"><input id="capture_signIn_redirect_uri_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="redirect_uri"><input id="capture_signIn_response_type_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="response_type"><input id="capture_signIn_flow_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="flow_version"><input id="capture_signIn_settings_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="settings_version"><input id="capture_signIn_locale_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="locale"><input id="capture_signIn_recaptcha_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_2tve61ocjs0r55htpcns25wj19ywspbgxtud44oj" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>